Vogelgrippe ? hier das Gegenmittel ACACIA RES-COMBIMTRX - 500 Beiträge pro Seite (Seite 2)

[whyso]

[posting]20.784.268 von [KERN]Codex am 17.03.06 23:54:49[/posting]Kern-die fangen bald Feuer

-------------------
DAS CBMX & NVAX POWERHOUSE wächst zusammen ....
--------------------------
CombiMatrix and Novavax collaborate
by: misc_info_06 03/17/06 11:09 am
Msg: 27031 of 27113

Pharmaceutical Business Review:

CombiMatrix and Novavax collaborate on vaccine production

10th November 2005

CombiMatrix, part of Acacia Research, is collaborating
with specialist biopharmaceutical company Novavax
on the development of a technique to
improve synthetic vaccine production,
possibly aiding the rapid production of a bird flu treatment.


Traditional flu-vaccine development involves the process
of viral amplification in chicken eggs,

followed by a LENGTHY process of inactivation,
sterilization, and packaging. This method IS
very time consuming and does NOT allow rapid response
to quickly evolving threats.

In the case of H5N1 bird flu,
the THREAT IS THAT THE STRAIN NOW PRESENT WILL MUTATE
or recombine to form a new strain that will be easily transmissible
among humans and have high mortality rates.

If such a new strain appears, traditional flu-vaccine
development and production will likely be TOO SLOW
to ramp up to cover the world`s need.


COMBIMATRIX IS DEVELOPING A TECHNIQUE designed to
IMPROVE THE PROCESS OF SYNTHETIC VACCINE PRODUCTION
BY TRACKING THE GENETIC FIDELITY of the genes
encoding the vaccine in the fermentation process.

such a method would be a SIGNIFICANT ADVANCE
FOR LARGE-SCALE SYNTHETIC PRODUCTION PROCESSES and

could help speed FDA regulatory processes.
The method is designed to be both inexpensive and fast.

CombiMatrix and Novavax are now collaborating
to test efficacy of the method on Novavax`s VLP process
for producing H5N1 bird-flu vaccine.


" CombiMatrix`s belief is that, for a variety of reasons,
THE WORLD NEEDS the ability to DESIGN NEW VACCINES
and to produce them much MORE RAPIDLY than it can today,"
said Dr Amit Kumar, president and CEO of CombiMatrix.

" Reasons include the possibility of rapidly evolving
natural threats such as bird flu and SARS
as well as increased terrorist activity throughout the world."

*****

http://www.pharmaceutical-business-review.com/article_news.a…
as far as I know this is all that has been disclosed
about the agreement. Although, during last CC Kumar discussed
the agreement, plus his personal history with NVAX CEO:

====================
Human & Birds samples from North America
were recently sent to CBMX for analysis by WHO;
CBMX H5N1 Findings on those samples have
already been sent back to WHO,
including level of pathegenity of strains.

These WHO Samples Results are to be published soon
====

Currently engaged in collaborative work
with NVAX, regarding Influenzia Drift Monitoring.

CEO`s of CBMX & NVAX are " personal friends"
and have worked together on Research projects
in the past, at MIT & Havard.

Vaccines are subjected to genetic drift,
which can render the vaccines under development ineffective.

CBMX Arrays are Very effective for monitoring such genetic drift.

CBMX & NVAX are Researching how to measure and control
genetic drift during vaccine development.
This collaborative Program will continue to expand
as NVAX vaccine development efforts
continue to grow.
====================

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065… 00656&action=m&mid=25639

perhaps will will find out more about NVAX & CBMX Plans
after there meeting in an India Biotech Summit at the end of March?

http://www.combimatrix.com/news_events.htm -----------------------
CombiMatrix and Novavax collaborate (2)
by: misc_info_06 03/17/06 11:16 am
Msg: 27034 of 27114

*****
Pharmaceutical Business Review:

Novavax enters flu vaccine research collaboration
16th February 2006

This preclinical data will supplement recent data published in collaboration
with the Centers for Disease Control and Prevention showing Novavax
influenza VLP vaccines can elicit a protective immune response.

http://www.pharmaceutical-business-review.com/article_news.a… *****

perhaps NAVX needs CBMX to SPEED UP the Gov`t Approval Process
afterall?

A mutating Virus in the Vaccine process
or in the Population at large could put
a serious " crimp" in Vaccine Production " turn-around" plans
*****

What is " Genetic Fidelity" ?

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065… *****

CDC`s BioSense Surveillance System,

CBMX Govt in-roads, Flu Chip Sales:

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065…
*****

CBMX`s Long-Term Potential of bringing many
OTHER VACCINES development programs into the 21st Century

http://finance.messages.yahoo.com/bbs?.mm=FN&board=160290065…

FAZIT: Ein 20$ Stock, den wir gestern für mickrigen 2,10$ erweren dürften
Ja nee, ist klar...STRONGEST BUY -(MIT NVAX als Partner)-am Markt überhaupt.

Schönes Wochenende ihr lieben,
Whyso

[isoldefroehn]

Guten Tag

Hab am Wochenende mal den Thread durchgelesen und
bin seit heute auch mit dabei (Erstposi) denke wir werden alte Höhen bald wieder erklimmen


auf steigende Kurse

Danke für die informativen Beiträge

[isoldefroehn]

Vorbörslich siehts ja ganz nett aus 2,29 US Dollar

http://data.inetats.com/ds/tools/bookviewer/javabook.jsp?STO…

[sneake]

hi leute

mal ne frage.beim kauf von acicia ist mir aufgefallen das es 2 verschiedene sind einmal
Acacia Research Corp. - Acacia Technologies
und dann die
Acacia Research Corp. - Combimatrix


gehoeren die zusammen?wenn ja warum gibt es 2 verschiedene wobei die andere sehr viel hoeher steht.

[tom924]

hi sneake!
hast du dich bei generex schon verabschiedet,und bist hier wieder drinnen?
wenn ja! dann schein wir ja den gleichen geschmack zu haben. die besten grüße! tom924

[sneake]

[posting]20.875.447 von tom924 am 20.03.06 20:43:16[/posting]hi

ne da bin ich noch drin.bei der akite hab ich ne schlaftablette genommen.grins.läuft prächtig oder?

kennst du dich dich mit der aktie hier aus?gibts da 2 versionen?

[whyso]

The chart is "dangerously" positive da bin ich froh nicht short zu sein...

NVAX 2 im Anlauf,
Whyso

[tom924]

[posting]20.875.619 von sneake am 20.03.06 20:55:57[/posting]bin bei generex bei 2,35$ mit etwa 100% plus raus. ich dachte man könnte sie um einiges wieder billiger bekommen.
jetzt schau ich leider hinterher.

zu acacia:dieser wert beschäftigt sich genauso mit der herstellung eines grippeimpfstoff, unter anderem auch mit einem gegenmittel für den H5N1 virus, und ist so ähnlich aufgestellt wie generex. deshalb bin ich nun hier investiert. ich bin auf diesen wert durch eine zeitschrift gekommen, genau wie du mit generex.
den anderen wert unter den namen acacia kenne ich leider auch nicht. ich glaube er hat aber nichts mit unserem wert zu tun.
ich hoffe acacia legt die gleiche perfomance wie generex hin! liebe grüße! tom924

[sneake]

[posting]20.875.962 von tom924 am 20.03.06 21:19:40[/posting]ich glaub die gehören irgendwie zusammen.weiß nur noch nicht warum.vieleicht ist acacia ne holding die bei an die börse gebracht hat???

[tom924]

[posting]20.876.032 von sneake am 20.03.06 21:23:45[/posting]dies wäre natürlich eine möglichkeit!

[sneake]

[posting]20.876.209 von tom924 am 20.03.06 21:37:46[/posting]wart mal ab wenn die vogelgrippe die staaten erreicht dann gehts noch höher!!!!

[nort.]

Hallo tom, sneake and all new ones,

CBMX und ACTG gehören zusammen. Im Q2 ist ein splitt geplant. D.h. CBMX wird eigenständig Somit wird endlich die Abhängigkeit zu Acacia aufgehoben und CBMX kann sich frei entwickeln. Was der Zusammenschluß zu Acacia gebracht hat, kann man im Chart sehen

Infos:

Thread: Acacia Research-(CBMX)-die CombiIMatrix- Vogelgrippe Play & rebounder 2006 ???

[tom924]

[posting]20.876.351 von sneake am 20.03.06 21:47:35[/posting]das ist nur mehr eine frage der zeit! ich warte schon länger drauf,doch der zugvogelwechsel ist noch lange nicht vorbei,und irgend ein H5N1-fink wird sich ganz sicher in die staaten verirren, und dann gehts los "alla ami-hysterie" und das ist gut für unsere aktie! na ja...so ist nun mal die börse!

[sneake]

[posting]20.876.375 von nort. am 20.03.06 21:49:34[/posting]danke

[tom924]

[posting]20.876.375 von nort. am 20.03.06 21:49:34[/posting]hi nort.
danke für den service! das macht unser investment auch noch lukrativer!

[sneake]

[posting]20.876.375 von nort. am 20.03.06 21:49:34[/posting]split???warum das denn?es sind doch 2 verschiedens wkn.warum dann split.

[tom924]

unser baby hat heute zu später stunde, noch unter großem volumen einen ordentlichen ruck nach vorne gemacht, dies läßt hoffen für die nächsten tage, denn einige charttechnische widerstände hat sie nun schon hinter sich gelassen!

[isoldefroehn]

Guten Abend

da kam am Ende ja noch ein richtiger Kaufrausch auf, SK 2,36 da kann man morgen ja dran anknüpfen, NVAX sieht ja auch super auch, hatte ich auch mal KK 2,54 Vk viel zu früh hoffe CBMX läuft ähnlich wie der "große" Bruder

Gute Nacht und bis morgen

[sneake]

großer bruder.irgendwie schnall ich das nicht.was machen denn die anderen?warum stehen die höher?warum wir tiefer?warum splitt?fragen über fragen.

[tom924]

alle "vogelgrippenaktien" haben heute außerordentlich gut performt. ist irgend eine nachricht zu diesem thema herausgekommen?

[isoldefroehn]

[posting]20.876.936 von sneake am 20.03.06 22:24:28[/posting]posting 512

[[KERN]Codex]

[isoldefroehn]

http://www.amex.com/?href=/othProd/prodInf/OpPiIndComp.jsp?P…

im dezember hatte cbmx einen anteil von 3,06% im Merrill jetzt sind es schon 4,28%

die wissen was gut ist

[sneake]

[posting]20.877.089 von isoldefroehn am 20.03.06 22:38:30[/posting]

[tom924]

[posting]20.876.936 von sneake am 20.03.06 22:24:28[/posting]die werden wohl irgend eine partnerschaft eingegangen sein um irgend ein produkt zusammen zu entwikeln,und combimtrx hat den namen von acacia angenommen. nun trennen sie sich wieder (produkt fertig oder erfolglos??) ich denke acacia wird dann auch wieder Combimtrx heißen.
mit split meinte nort. trennen.
ist alles nur meine version die ich mir zusammengestoppelt habe.

[nort.]

[posting]20.877.124 von tom924 am 20.03.06 22:41:57[/posting]CBMX ist eine subsidiary von Acacia gewesen. Hing an deren Busen, bis CBMX das Laufen gelernt hat. Nun ist es endlich soweit CBMX wird eigenständig und erwachsen.

[sneake]

[posting]20.877.166 von nort. am 20.03.06 22:46:50[/posting]und sind sie schon erwachsen dafür genug?

[sneake]

[posting]20.877.166 von nort. am 20.03.06 22:46:50[/posting]haben wir einen vorteil von der trennung außer der selbsständigkeit?z.b gratis akiten?

[nort.]

http://biz.yahoo.com/bw/060109/20060109005233.html?.v=1

Acacia Research Announces Plan for CombiMatrix to Become Independent Public Company
Monday January 9, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 9, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that its Board of Directors has approved a plan for its wholly-owned subsidiary, CombiMatrix Corporation, to become an independent public company. Acacia expects to complete the transaction in the second quarter of 2006 subject to receiving a satisfactory tax opinion from legal counsel and completing the required filings with the Securities and Exchange Commission. If the conditions are met, Acacia will redeem all of the issued and outstanding shares of Acacia Research-CombiMatrix common stock (CBMX) for all of the common stock of CombiMatrix Corporation, which will register its stock under the Securities Act of 1934 and plans to list its shares for trading on Nasdaq.

ADVERTISEMENT
"The Board of Directors decision enables CombiMatrix Corporation to become an independent public company. This will benefit both companies by eliminating the risk factors associated with the current capital structure," commented Paul Ryan, Chairman and CEO of Acacia. "The separation of the two companies should enable each company to optimize its own identity and business strategy, making an investment in the companies more attractive to investors," concluded Mr. Ryan.


Dr. Amit Kumar, President and CEO of CombiMatrix, said, "As an independent public company, CombiMatrix Corporation should have better visibility in the health care market and enable the public markets to better value the company."

[sneake]

Index Components as of: 03/17/06

Merrill Lynch Nanotech Index - NNZ


Company Name Symbol % Weighting

Novavax Inc NVAX 4.57%
Nanogen Inc NGEN 4.47%
Acacia Research-Combimatrix CBMX 4.28%
Arrowhead Research ARWR 3.86%
pSivida Ltd. (ADS) PSDV 3.84%
Ultratech Inc UTEK 3.80%
Headwaters Inc. HW 3.75%
Harris & Harris Group Inc TINY 3.74%
Pharmacopeia Inc ACCL 3.73%
Westaim Corp WEDX 3.70%
Mts Systems MTSC 3.69%
Kopin Corp KOPN 3.68%
Amcol Intl ACO 3.67%
Nanophase Technologies NANX 3.65%
Cabot Corp CBT 3.65%
Veeco Instruments VECO 3.63%
Skyepharma Plc Ads SKYE 3.62%
Jmar Technologies JMAR 3.60%
Altair Nanotechnologies ALTI 3.54%
Immunicon Corp IMMC 3.53%
Symyx Technologies SMMX 3.52%
Nve Corp NVEC 3.48%
Tegal Corp TGAL 3.48%
Fei Co FEIC 3.42%
Biosante Pharmaceuticals BPA 3.39%
Lumera Corp LMRA 3.39%
Flamel Technologies Ads FLML 3.32%

[sneake]

[posting]20.877.206 von nort. am 20.03.06 22:51:58[/posting]bist schon länger vertraut mit der aktie?ich erst seit heut vormittag.

[nort.]

[posting]20.877.232 von sneake am 20.03.06 22:55:03[/posting]Habe meine letzte Position im Dezember gekauft. Nun genieße ich nur noch

[sneake]

[posting]20.877.206 von nort. am 20.03.06 22:51:58[/posting]hast du den großen bruder auch in deinen depot?wem gehören dann die ganzen patente?unserem baby oder dem anderen baby.

[nort.]

[posting]20.877.246 von sneake am 20.03.06 22:57:24[/posting]Nein, der große Bruder ist uninteressant. Bird flu ist hier die Initialzündung. Schaut Euch an, woher die Aktie kommt und hoffendlich auch wieder hingeht

[nort.]

[posting]20.877.246 von sneake am 20.03.06 22:57:24[/posting]Patente gehören beiden. Wobei eher ACRG auf Patente speziallisiert ist. Bei CBMX ist es ein Nebengeschäft.

http://www.deraktionaer.de/xist4c/web/Combimatrix---Spiel-au…

[sneake]

[posting]20.877.262 von nort. am 20.03.06 22:59:31[/posting]ja und vor allem wenn die vögel die usa erreichen.

[sneake]

und wem gehören die 140 patente?

[[KERN]Codex]

[posting]20.877.262 von nort. am 20.03.06 22:59:31[/posting]Da muss erstmal richtig Volumen rein

[sneake]

Mit einer speziellen Technologie von Combimatrix können synthetische Impftsoffe künftig wesentlich schneller hergestellt werden. In der Bilanz werden jetzt die Erfolge der vergangenen Monate deutlich sichtbar.

Die Vogelgrippe breitet sich in Asien derzeit mit einer hohen Geschwindigkeit aus. Nicht selten sind auch Menschen von der Krankheit betroffen. Insgesamt arbeiten weltweit neun Pharmaunternehmen an einem Impfstoff, um die Epidemie in den Griff zu bekommen. Allerdings ist das gar nicht so leicht, denn das Virus kann andere Erreger in sein Erbgut aufnehmen und sich damit in relativ kurzer Zeit verändern. Ein vormals geeigneter Impfstoff kann nach einer Mutation seine Wirksamkeit komplett verlieren. Das US-Unternehmen Novavax - der aktionär berichtete in Ausgabe 44/05 - hat erste Erfolge in der Entwicklung eines Impfstoffes gegen das H5N1-Virus erzielt. Allerdings befindet man sich erst in der präklinischen Phase. Das Produkt wäre damit erst in vielen Jahren auf dem Markt.

Combimatrix macht`s möglich
Die Zusammenarbeit mit Combimatrix könnte den Entwicklungsprozess allerdings enorm beschleunigen. Der Hersteller von Biochips ist im Besitz einer Technologie, mit der die Herstellung synthetischer Impfstoffe deutlich schneller als bisher möglich ist. Zudem kann man damit die genetische Zusammensetzung exakt kontrollieren und so schneller auf Mutationen reagieren. Für Combimatrix läuft es gut in diesem Jahr: Im August hat man seinen ersten DNA-Synthesizer auf den Markt gebracht. Mit ihm können Unternehmen in ihren eigenen Forschungszentren Mikrodatenträger mit biomolekularen Informationen anlegen. Im dritten Quartal erhielt man einen weiteren Auftrag von der Air Force zur Entwicklung und Produktion eines Biochips zum Aufspüren von Krankheitserregern, die sich auf Atemwege und Wunden ausbreiten.


Umsatzschub
Die Erfolge der vergangenen Monate haben das Zahlenwerk von Combimatrix spürbar beeinflusst. So stieg der Umsatz im dritten Quartal 2005 gegenüber dem Vorjahreszeitraum um 94 Prozent auf 1,40 Millionen Dollar. Zwei Drittel davon erzielte Combimatrix mit Regierungsaufträgen. Der Verlust blieb mit 3,88 Millionen Dollar auf dem Niveau des Vorjahresquartals. Mit einem Cash-Bestand von 24,7 Millionen Dollar verfügt man zudem ein über ein solides finanzielles Polster.

Nicht zögern
Die Combimatrix-Aktie reagierte auf die Kooperation mit Novavax mit einem deutlichen Kurssprung, jedoch konnte der Abwärtstrend nicht endgültig gebrochen werden. Allerdings verhinderte die Unterstützung bei 1,50 Euro weitere Rücksetzer. Anleger scheinen das ganze Potenzial des Unternehmens bislang nicht erkannt zu haben. Wer auf die Zukunft von Combimatrix setzen will, sollte beim aktuellen Kurs nicht zögern. Der Wert empfiehlt sich jedoch ausschließlich für spekulative Investoren.

[sneake]

interessant ist das sie auch noch im nano bereich mit tätig sind.

[sneake]

[posting]20.877.306 von [KERN]Codex am 20.03.06 23:04:23[/posting]das kommt noch.warts ab.

[sneake]

[sneake]

[hasi22]

komme soeben von einem Vereinsmeeting; das macht je gewaltig Freude
(ein bekannter Börsenbrief hat CBMX drauf !!!)

[bubu]

Glückwunsch allen Investierten,

bin ja (leider) vor wenigen Wochen ausgestiegen.

Gruß
bubu

[sneake]

[posting]20.877.519 von bubu am 20.03.06 23:43:02[/posting]warum????

[sneake]

ist einer von euch 2 länger dabei schon?

[sneake]

[posting]20.877.507 von hasi22 am 20.03.06 23:40:03[/posting]du hasi oder?du bist doch schon länger vertraut mit der aktie oder?

[sneake]

hätte paar fragen.

[bubu]

[posting]20.877.524 von sneake am 20.03.06 23:44:21[/posting]Weil ich doof bin,

dachte, die paar toten Enten auf Rügen, die den Anstieg vor wenigen Wochen gestartet hatten, wäre nicht von Dauer gewesen. Hatte auf einen Rücksetzer spekuliert und den Widereinstieg verpasst.

Folge aber dennoch der Nachrichtenlage und lese still weiterhin mit.

Gruß
bubu
&nite.

[sneake]

[posting]20.877.550 von bubu am 20.03.06 23:47:55[/posting]wart mal ab wenn die vögel die staaten erreichen.

[hasi22]

Hallo Freunde,

habe damals gekauft und zwar weil in Yahoo plötzlich grosse Volumen auftauchten, und nachher den Thread eröffnet (was wohl mein erfolgreichster werden wird ) und dann zum Glück einfach gehalten. Dies, weil mir das Produkt zu gut schien.

Habe heute die schweizerische Regierung angefragt, ob das Proukt bekannt ist und warum man noch immer Proben nach England sendet, binn gespannt.

Halte immerhin etwa 5% meines Depots und überlege also schwer beim nächsten Dipp nachzukaufen.

und nun eine Gute Nacht Hasi

[Tuttobene]

Glückwunsch erstmal an die Investierten.
Was meint ihr, lohnt sich noch ein Einstieg? Wenn ich mir so anschaue, wo das Teil herkommt, denke ich doch allemal oder?

[sneake]

[posting]20.878.010 von Tuttobene am 21.03.06 06:59:08[/posting]morgen tutto

auf jeden fall.das ist erst der anfang.das ding wird genauso laufen wie generex.merryl lynch hast hat sie sogar höher aufgestockt im listing.siehe tabelle weiter unten.

[whyso]

[posting]20.878.010 von Tuttobene am 21.03.06 06:59:08[/posting]@Tuttobene,
"Was meint ihr, lohnt sich noch ein Einstieg?" der Artikel unten genaustens durchlelesen, dann selber in alle Ruhe entscheiden

http://www.dddmag.com/showpr.aspx?PUBCODE=016&ACCT=160000010…

Die angestrebte Diagnostics Marktanteile mit NVAX zusammen erfasst sowohl der Vaccine, Sars, HIV & auch alle flächendeckende Grippal-Infektions-märkte...

Nun rechne mal...
Whyso

[sneake]

[posting]20.878.112 von whyso am 21.03.06 07:37:39[/posting]morgen wyso

bist du schon länger mit den unternehmen vertraut?

[Tuttobene]

Danke für die Hinweise Jungs, ich werde wohl die erste Order um 9.00 reinstellen.

[Tuttobene]

So wie ich die Amis kenne geraten die in Panik, wenn eine Quitscheente mit Bauch nach oben schwimmt.
Somit dürfte der Vogelgrippehype wohl erst anfangen.

[sneake]

[posting]20.878.167 von Tuttobene am 21.03.06 07:48:35[/posting]

[sneake]

ich denk das wird die biotecrakete 2006 mit generex.

[Tuttobene]

[posting]20.878.250 von sneake am 21.03.06 08:00:52[/posting]Gut möglich, und bei generex bin ich gestern ja auch noch frühzeitig rein
Da müssen heute wohl meine Patriot dran glauben

[whyso]

[posting]20.878.134 von sneake am 21.03.06 07:41:53[/posting]Yes-Quasi von Anfang an

[Tuttobene]

[posting]20.878.356 von whyso am 21.03.06 08:10:16[/posting]whyso,
du scheinst hier der zu sein, der sich am längsten mit dem Teil beschäftigt.
Ich weiss, es klingt blöd und lemminghaft, aber was glaubst du hat denn der Wert für Potential?

[sneake]

[posting]20.878.286 von Tuttobene am 21.03.06 08:04:31[/posting]du bist noch gestern bei generex rein?die läuft doch schon seit tagen.und haust die patrioten weg???

[sneake]

[posting]20.878.437 von Tuttobene am 21.03.06 08:17:12[/posting]hab auch fragen über fragen aber nicht nach dem potenzial sondern warum es 2 gibt.warum sie getrennt werden.warum steht die andere höher.und und und.

[Tuttobene]

[posting]20.878.469 von sneake am 21.03.06 08:19:22[/posting]Bin leider erst gestern drauf gestoßen und die Patriot scheinen ausgelutscht zu sein.

[sneake]

[posting]20.878.539 von Tuttobene am 21.03.06 08:24:16[/posting]Meinst du ?

[Tuttobene]

[posting]20.878.567 von sneake am 21.03.06 08:26:24[/posting]schwer zu sagen, aber die MK ist mir zu hoch und der Ausgang der Verhandlungen zu unsicher.

[sneake]

[posting]20.878.590 von Tuttobene am 21.03.06 08:28:06[/posting]mhh

[Tuttobene]

[posting]20.878.637 von sneake am 21.03.06 08:31:31[/posting]MK ist mehr als 500Mio€ und das ist mir definitiv zu hoch bewertet.
War für mich eh nur ein trade

[sneake]

[posting]20.878.801 von Tuttobene am 21.03.06 08:44:30[/posting]ja ich will noch die dividende abfassen.lohnt sich bei mir da ich seit wenigen cents drin bin.

[Tuttobene]

[posting]20.878.862 von sneake am 21.03.06 08:49:07[/posting]Ja dann ist das natürlich keine Frage, da würd ich auch dabei bleiben.
Nur ich hab das Teil jetzt 5x getradet und das reicht mir.

[Aptamilla]

[posting]20.878.910 von Tuttobene am 21.03.06 08:51:54[/posting]In München wartet jemand auf den Osterhasen!

[sneake]

showtime

[Tuttobene]

[posting]20.879.141 von Aptamilla am 21.03.06 09:05:11[/posting]Schau gleich mal

[Tuttobene]

Fra 1,95. Das geht grad noch

[sneake]

[posting]20.879.237 von Tuttobene am 21.03.06 09:10:05[/posting]bist drin?

herzlichen glückwunsch.

[Tuttobene]

Und drin bin ich

[sneake]

werd auf alle fälle auch noch mal zukaufen aber werd erst mal heut nachmittag abwarten was da abeht.hast noch ein zockerwert zu empfehlen?geile story?

[janfer]

[posting]20.879.493 von sneake am 21.03.06 09:20:59[/posting]Schau Dir mal die SEIH / GWGO u. GZFX an.

[Tuttobene]

[posting]20.879.493 von sneake am 21.03.06 09:20:59[/posting]Imho nix, was ich guten Gewissens empfehlen könnte.
Ich warte auch noch bis US Eröffnung und lege dann nochmal nach. Es sei denn, es kommt eine SL Welle.
Ist aber bei dem Volumen nicht zu erwaren.

[sneake]

[posting]20.879.604 von Tuttobene am 21.03.06 09:26:06[/posting]glaub ich auch ned.der trend stimmt und ddas volumen auch einigermaßen.

[Tuttobene]

In Mü noch welche für 1,93 bekommen

[sneake]

[posting]20.879.724 von Tuttobene am 21.03.06 09:31:26[/posting]bist wohl schwer am einkaufen was?hehehehe

[sneake]

Die MK ist ein witz!!!!!!

98 mio!!!!
bei knapp 40 mio außenstehenden aktien und interesse der insder!!!!

[Tuttobene]

[posting]20.879.789 von sneake am 21.03.06 09:34:16[/posting]Na wenn in München einer verschenkt

[sneake]

ole ole ole ole

[Tuttobene]

[posting]20.879.841 von sneake am 21.03.06 09:36:17[/posting]Die MK lasse ich mir schon eher gefallen als die bei Patriot

[sneake]

[posting]20.880.314 von Tuttobene am 21.03.06 09:58:26[/posting]ja stimmt.und es ist ein Nasdaq wert.das mit merryl lynch weißt du oder?

[Tuttobene]

[posting]20.880.772 von sneake am 21.03.06 10:23:58[/posting]ja weiss ich, hab mich hier schon eingelesen

[sneake]

[posting]20.881.055 von Tuttobene am 21.03.06 10:39:21[/posting]

[Tuttobene]

hab jetzt den ganzen OTC Scheiss rausgehauen und in Acacia und Generex gesteckt

[sneake]

[posting]20.881.196 von Tuttobene am 21.03.06 10:46:49[/posting]echt?lol

[Tuttobene]

Und die 2 ist auch schon da

[sneake]

[posting]20.881.196 von Tuttobene am 21.03.06 10:46:49[/posting]was hälst du von sunwin?

[Tuttobene]

[posting]20.881.283 von sneake am 21.03.06 10:52:21[/posting]Hab ich auch rausgehauen. Die dürfte vorerst mal gelaufen sein.
Einzig Digital und Far east hab ich noch

[sneake]

wow was passiert heut bei den amis wohl???

[Tuttobene]

[posting]20.881.951 von sneake am 21.03.06 11:24:56[/posting]Wird hoffentlich weiter steigen, hier schon 2,02

[sneake]

geh jetzt essen bis später.

[GoofMan]

Dr Amit Kumar redet heute auf der "Invest Northwest".

Bell Harbor International Conference Center
March 21, 2006 - Seattle, Washington
Dr. Amit Kumar Presenting


USA premarket derzeit 2.35 x 2.47 last trade 2.38

Sieht so aus als würden wir den positiven Trend von gestern fortsetzen.

[sneake]

[posting]20.888.914 von GoofMan am 21.03.06 14:12:07[/posting]kann man das irgendwo live mitverfolgen?

[sneake]

[posting]20.888.914 von GoofMan am 21.03.06 14:12:07[/posting]oder wird ne news kommen.mhh lecker.

[sneake]

geiles teil vor allem weil es 2 bereiche abdeckt.nano und biotech.

[GoofMan]

Ja es gibt einen Live Webcast, leider haben die vergessen die Uhrzeit anzugeben:

http://www.combimatrix.com/news_events.htm

und dann oben auf "Invest Northwest" klicken.


Ach ja: 2.40 x 2.47 aktuell.

[sneake]

CombiMatrix’s core technology is a specially modified semiconductor adapted for biological applications. These integrated circuits contain arrays of microelectrodes that are individually addressable using embedded logic circuitry on the chip. Placed in a specially designed fluidic chamber, the chip digitally directs the molecular assembly of biopolymers in response to a digital command.

Under a controlled process developed at CombiMatrix, each microelectrode is addressed to selectively generate chemical reagents by means of an electrochemical reaction. These chemical reagents facilitate the in situ synthesis of complex molecules such as DNA oligonucleotides. These molecules are synthesized within a proprietary Porous Reaction Layer (PRL) that coats the chip. Under the direction of a PC the CombiMatrix chip rapidly synthesizes over a thousand different molecules in parallel, each above a distinct electrode. Since a different product can be synthesized at each site, the technology eliminates the need to synthesize different products in individual tubes by conventional methods. The parallel process drastically reduces the cost and time of synthesizing hundreds or thousands of different molecules.



A small section of the semiconductor surface is shown above containing 16 electrodes where chemical reactions take place. Each electrode (highlighted in red) is 94-microns in diameter and controlled by individual electronic circuits embedded in the semiconductor. A software-controlled process that addresses any number of electrodes in parallel activates electrodes according to the molecular structure that needs to be synthesized. Once an electrode is addressed, chemical reagents are generated directly at that site under a controlled process. These reagents are used to control the assembly of a variety of different chemicals (including DNA) in situ. The figure above demonstrates the electrical activation of two electrodes. Subsequent generation of chemical reagents occurs at these sites suitable for synthesis of complex molecules such as DNA oligonucleotides.


--------------------------------------------------------------------------------

CombiMatrix has also developed the necessary technologies that enable high-throughput and reliable synthesis of biomolecules on these chips. Our Porous Reaction Layer (PRL) Technology permits synthesis and attachment of biomolecules within the layer above the semiconductor surface. Virtual Flask Technology confines the reagents that are generated at each electrode within a defined virtual column. Finally, biomolecules such as DNA oligonucleotides are rapidly synthesized and used in a variety of Microarray Applications.

[GoofMan]

Last trade 2.47

Bisher alles bei sehr geringem Volumen, aber die Tendenz gefällt mir

[sneake]

Lab-on-a-Chip

Arrays of individually addressable microelectrodes permit synthesis of hundreds or thousands of different molecules in parallel.



Porous Reaction Layer (PRL)

Biocompatible layer that supports the attachment of synthesized molecules.




Virtual Flask

A process that confines chemical reagents within a virtual flask over each microelectrode.



DNA Microarrays

Arrays of oligonucleotides capture molecules synthesized on the chip for use in genomic and proteomic applications.

[sneake]

Defense Applications

The powerful technology of the CustomArray™ platform combined with CombiMatrix’s advances in electro-chemical detection is meeting a crucial national need. CombiMatrix is revolutionizing detection technologies for biological and chemical threat agents.

CustomArray™, as a CMOS chip, is a versatile transducer that can convert electrical signals into electrochemical reactions at each electrode. Conversely, circuitry on the microarray can convert an electrochemical reaction above an electrode into a signal.

CombiMatrix is now developing electro-chemical based instruments and assays for the genomic identification of biothreat agents (viruses and bacteria) and serological assays for toxins, viruses and bacteria.

Electro-chemical detection turns the microarray into the sensor. Complex, expensive, and less-than-robust optical readers are not needed. Microarray technologies can now be configured into a variety of instrument designs to support fixed and mobile laboratories and stand-alone detection systems.

With over 12,000 electrodes available for individual assay results, CustomArray™ readily supports multiplexed genomic and serological assays against all categories of biothreat agents. CombiMatrix scientists and engineers continue to investigate and develop new detection strategies to counter the known and unknown threats with a reliable, sensitive, and robust detection platform.

[sneake]

Nanotechnologie

The emerging field of nano-scale engineering and science has generated considerable excitement recently. Though definitions vary, this field is focused on materials, devices, structures, and processes that occur on the scale of atoms or groups of atoms. The size regime is on the order of nanometers. Another common term used to describe activity and research in this field is Micro-Electro-Mechanical Systems (MEMS). Our contribution to this field is our semiconductor based array technology that enables the preparation of materials with nano-scale control.

CombiMatrix’s microarray technology allows for the parallel synthesis of large numbers of nano-structured materials. These materials can then be tested using the same chip-based technology. These activities are focused on materials that could be useful for applications in the fields of electronics, energy conversion, energy storage, catalysis, and others. Similar to life-science applications, our technology enables us, our partners, and customers to increase the throughput of discovery and screening activities.

The conventional approach to materials discovery involves synthesis of a material, followed by testing, successive cycles of synthesis, and more testing. This process is very labor intensive, costly, and inefficient. Our approach enables the synthesis of hundreds to thousands of materials in parallel followed by testing of all of those materials at once, thus allowing for greater efficiency.

Also, since our technology utilizes our microarray platform, which consists of arrays of microelectrodes, all syntheses are performed electrochemically. Therefore, controlling currents, voltages, and the ways in which the materials are applied to each electrode can influence the structure and morphology of the synthesized materials. This exquisite control should enable the fabrication of materials with unique properties.

The following figures depict an example of the types of experiments that can be performed using our platform technology. The first image shows a white-light, magnified view of a section of one of our arrays on which materials have been fabricated. We used this array to polymerize an organic molecule known as a pyrrole. Polymerization times (0.5-30 seconds) and applied voltages (0.25-0.6 V vs. a reference) were varied across the array. On this particular chip, several hundred different compositions of polypyrroles were fabricated, although the image shows only 100 compositions in a 10 by 10 section of the chip. The resulting polypyrroles are conducting polymers, which have applications in many areas such as battery and fuel cell technology. The electronic, physical, and chemical properties of conducting polymers are known to be very dependent on the methods and conditions used to synthesize and process them. In this particular case, without even doing any complex analysis, we can see that the optical appearance of each sample, polymerized at the individual electrodes, are different.


The second figure is a higher magnification view of a 3 by 3 section of the chip after polymer synthesis. In this figure, the underlying electronics are visible. The actual polymer (circular feature in the middle of each unit cell) is displaced slightly from the site of the electrode (circular feature on the top left of each unit cell) since an overlayer was used. The reasons for this are proprietary. The diameter of the polymer spots in each figure is about 90 micrometers.

Our strategy in this area of nano-structured materials is similar to our strategy in the life-science arena. We plan to leverage our technology, intellectual property, and capabilities with those of our partners. We plan to discover new materials, as well as build workstations that can be sold to customers who will undertake their own discovery efforts using our microelectrode arrays. To this end, we have established a strategic relationship with NanoMaterials Discovery Corporation (NDC) to collaboratively perform our discovery research, as well as build a workstation. NDC has assembled intellectual property and capabilities that we feel will synergistically help advance this program.

[GoofMan]

Es geht los:

2.50 x 2.58

[sneake]

Drug Development

CombiMatrix is able to synthesize large libraries of RNAi compounds in parallel. This allows testing of the biological function of each of these molecules and empirically determine the most effective approach. These "molecular libraries" are synthesized using our parallel synthesis technologies on a semiconductor biochip. The design of the RNAi molecules is guided by a host of bioinformatic tools developed to significantly reduce the likelihood of unintended side effects and maximize efficacy. Our adaptable chip platform enables us to test the efficacy of large numbers of compounds then redesign and keep evolving the design of our RNAi molecules.

CombiMatrix is working to develop partnerships with organizations with the most promising delivery technologies to bring our siRNA compounds to clinical trials.

CombiMatrix has integrated its semiconductor-based parallel oligonucleotide synthesis platform with streamlined screening activities for the discovery and development of novel RNAi-based therapeutics. The CombiMatrix Drug Discovery Program integrates the following functions:

Gene target or pathogen identification
Bioinformatics construction of sequence libraries
Chip-based parallel synthesis of siRNA compounds
Parallel in-vitro siRNA library screening
Optimization and validation of lead siRNA compounds using CombiMatrix`s customizable gene expression microarrays
Advancement of lead compounds into clinical development with pharmaceutical partners
Different siRNA compounds are produced in parallel for each target gene using CombiMatrix`s microarray-based in situ synthesis platform. The parallel synthesis approach permits cost-effective production and screening of a large number of siRNA compounds at one time. Small and large pools of different siRNA compounds are generated that specifically target a single gene or entire pathogen genomes.

Suitable compounds for gene silencing are identified using in-vitro screening assays. In addition, CombiMatrix`s customizable gene expression microarrays are used to determine the specificity of gene silencing within target systems. For example, an ideal siRNA compound has complete specifity for the target it is intended to inhibit and does not affect any other gene in the system. CombiMatrix`s customizable gene expression microarrays are used to determine the specificity of each lead RNAi candidate using a comprehensive approach.

[isoldefroehn]

http://www.us-aktien.com/realtime.htm

Realtime USA

Grüße

[sneake]

und fuer die neuen stell ich nun die produkte mal rein so das sie nicht mehr suchen brauchen.

[sneake]

Custom Array Synthesizer

The CustomArray™ Synthesizer is a semiconductor based custom oligonucleotide microarray synthesizer used for genetic analysis applications. Synthesis occurs on a blank CombiMatrix semiconductor chip using standard phosphoramidite chemistry methods.

[GoofMan]

Mal sehen ob sich die premarket Tendenz nach der Eröffnung bestätigt, in Deutschland sollte das rein nach Umrechnung momentan ca. 2,06 ergeben. Schauen mir mal wann und ob wir nachziehen und wie sich das im Laufe des Tages entwickelt.

Ach ja durch all die Copy & Paste Attacken hier im Thread (muss das sein das man die ganze CBMX Homepage hier in Teilen reinkopiert??) ist das untergegangen:

Dr Kumar ist heute auf einer Investment Show und wird Combimatrix dort vorstellen, Link zum Live webcast:

http://www.combimatrix.com/news_events.htm

Oben das blaue Invest Nortwest anklicken.

[sneake]

CombiMatrix Corporation’s CustomArray™ is a high quality, completely customizable microarray that provides a cost effective and timely solution for microarray users. Oligonucleotide probes can be defined and designed by the user and supported by the open source CombiMatrix probe design system at no additional cost. In addition, the platform takes advantage of equipment used for scanning microscope slide microarrays that avoids the necessity of purchasing additional equipment. The CustomArray™ is manufactured under stringent conditions, and each and every array is quality controlled. The turn around time is typically less than thirty days.



CustomArray™ uses a specially modified “CMOS” semiconductor to direct the molecular assembly of a specific sequence of DNA bases in response to a digital command. Each feature on the array (a microelectrode) is digitally addressed to selectively generate acid, by means of an electrochemical reaction which, in-turn, controls the detritylation reaction during phosphoramidite synthesis. A software program is used to control the microelectrodes, and thus, the detritylation pattern applied on the chip during synthesis.



The CustomArray™ 12K is the premier microarray format in the market for changing content and multi-iteration updates. Our customers tell us that we have the most cost effective microarray in the business for customized content.

CustomArray’s superior flexibility and performance is designed to overcome the limitations and lack of flexibility of currently available microarrays that support researchers. In addition to its superior performance, the CustomArray™ 12K offers:

Open architecture on chip design
Rapid results because new chips can be built very quickly
Compatibility with common sample preparation techniques and hybridization buffers
No minimum order requirements, up front fees, or special equipment/system purchases
Bioinformatic tools included in the cost of the array
In addition, the CustomArray™ 12K is manufactured under industry leading quality standards.

CombiMatrix CustomArray™ 12K system is economical, simple, requires less labor, and design-to-results is rapid. Users can update and change probe designs at any time and arrays can be updated as new sequences are available. CustomArray™ users can research any gene, any genome or any sequence.

[GoofMan]

[posting]20.889.251 von sneake am 21.03.06 14:32:26[/posting]sneake sorry, das NERVT

[sneake]

CombiMatrix Influenza A Research Microarray

In the face of concerns over an influenza pandemic, identification of virulent influenza isolates must be obtained quickly for effective responses. Knowledge of the exact strain, origin of the strain and probable characteristics of the virus are critical for surveillance of a disease outbreak and preventing the spread of the disease. Rapid subtype identification of flu is not always straightforward. Simple serological tests on infected individuals are awkward to administer and are an ineffective tool for monitoring viruses undergoing a high rate of mutation or rapid recombination. RT-PCR assays have better sensitivity but are problematic in scenarios where new strains of virus emerge or mixtures of viruses exist.

In many situations the identification of the circulating subtype is not sufficient and specific knowledge of the genetic makeup of the virus is required. For example, the avian H5N1 virus ("Bird Flu") has significant potential for further recombination with common human strains (such as H3N2) or other non-human strains common in avian populations (H7 and H9 strains).The H5N1 subtype is also difficult to identify because of the lack of sensitivity and specificity of many of the commercial tests. In addition, genotype Z, the dominant H5N1 virus genotype currently circulating in Vietnam and Thailand, contains a mutation that is associated with resistance to amantadine and rimantadine. Also, because of the high susceptibility in humans and resistance to antibiotics of this isolate, neuraminidase inhibitors must be given within 48 hours of onset of illness to be effective. Thus rapid and specific identification of this subtype and accurate sequence information is crucial for proper treatment.

CombiMatrix has also developed a semiconductor-based DNA chip, the CombiMatrix Influenza A Research Microarray, that can detect and accurately type flu strains with hemagglutinin subtypes 1 through 15 and neuraminidase subtypes 1 through 9 using a protocol that requires less than four hours start to finish. In addition to providing very high resolution information on genotype of any given flu strain, it can also provide information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu.

This system is available to the flu researcher as a tool or as a service from CombiMatrix (for research use only at this time). This system is also being developed as a field deployable biodetector using electrochemical techniques for analysis. This chip can be employed as an adjunct to existing technology: to type difficult or ambiguous samples of flu, provide greatly increased confidence in RT-PCR assays or study genetic drift in a flu virus as it moves through a population.



The CombiMatrix Influenza A Research Microarray is based on CustomArray 12K™ array format. The specific oligonucleotide probe sets are designed for all known subtypes of hemagglutinin and neuraminidase from the influenza A viruses. The virus genetic material is amplified by PCR, and the resultant target nucleic acid mixture is hybridized to a CombiMatrix Influenza A Research Microarray chip. The enzymatic reactions that are performed on the chip as steps of CombiMatrix Hyb & Seq™ procedure allow for short hybridization times and rapid detection. The whole assay may be performed in less than 4 hours.

[sneake]

Performance of Influenza Microarray

The CombiMatrix Influenza A Research Microarrays were hybridized with genetic material from two of influenza A subtypes: subtype 1, H2N2, and subtype 2, H15N9, respectively. The detected hybridization signals resulted in unambiguous determination of influenza subtypes.

[sneake]

oder schaut gleich doch hier.ist mir doch zu anstrengend.

http://www.combimatrix.com/

[sneake]

[posting]20.889.265 von GoofMan am 21.03.06 14:33:24[/posting]Also du willst immer alle paar minuten die kurse sehen?ist das informativer fuer dich?

[sneake]

[posting]20.889.247 von GoofMan am 21.03.06 14:32:18[/posting]es gibt nun mal faule leute die nicht erst rumsuchen wollen im web sondern immer alles gleich im thread haben wollen.

[sneake]

Na gut dann halt ich eben mein Maul.

[Tuttobene]

[posting]20.889.363 von sneake am 21.03.06 14:39:11[/posting]ist schon OK sneake. Infos kann man immer brauchen

[isoldefroehn]

[isoldefroehn]

Premarkt

2,45 / 2,52 last 2,51

auf einen grünen Tag

[GoofMan]

Mal sehen wie grün, jenachdem was Dr Kumar heute auf der Präsentation so von sich gibt.

[Tuttobene]

Vorbörslich jedenfalls recht ordentlich. Generex übrigends auch

[GoofMan]

Ich hoffe er erwähnt "Bird Flu" und die Pläne der USA, die Tests auf den Virus bei Tieren deutlich auszuweiten (war neulich auf CNN).

Wenn die US Regierung den CBMX Scanner bestellt, dann hoffe ich auf alte Höchststände der Aktie.

[isoldefroehn]

los gehts!!!!!!!!!!!!!!!!!!!!

[GoofMan]

Infos zur Präsentation heute:

Zeit: 2:20 - 2:40 pm EST



"Invest Northwest is the leading investment conference for Pacific Northwest life science community. Invest Northwest is in its fourth year of facilitating relationships between bioscience investment professionals and medical device, biotechnology and related companies. This conference provides bioscience companies an ideal venue to network, identify opportunities and expose the investment community to the width and breadth of this regions’ life science sector. Companies present business plans to an international audience of investors ranging from certified angels, venture capitalists, mezzanine level funds, pension fund managers, analysts and institutional investors."

[isoldefroehn]

mal sehen ob es bei geschlossenem Gap dreht?

[isoldefroehn]

gap ist zu, für manche ist das ja immer sehr wichtig

[isoldefroehn]

2,34 / 2,47

ganz schöner Spread

[GoofMan]

[posting]20.890.981 von isoldefroehn am 21.03.06 16:04:50[/posting]Wenn Du auf den Link von vorher schaust dann beachte, daß das nur ein ECN ist, also NICHT den aktuellen best market Stand wiedergibt!!

Grundlagen info dazu

http://www.day-trading.de/Ecns.php

[isoldefroehn]

[posting]20.891.228 von GoofMan am 21.03.06 16:18:04[/posting]danke für den Hinweis

gibts den die Möglichkeit US-Realtime zu sehen (kostenfrei)


Danke und grüße

[GoofMan]

[posting]20.891.592 von isoldefroehn am 21.03.06 16:38:18[/posting]Kostenlos soviel ich weiss nicht, aber die ECN Kurse sind als Näherung zumindest mal ganz gut brauchbar.

[italy05]

http://www.advfn.com/quote_Acacia-Research_NASDAQ_CBMX.html


Ist kostenlos

[GoofMan]

[posting]20.891.693 von italy05 am 21.03.06 16:43:05[/posting]Das schon, aber um 15 Minuten verzögert. (siehe Hinweis unten und Vergleich mit echten RT Quotes)

[sneake]

[posting]20.891.592 von isoldefroehn am 21.03.06 16:38:18[/posting]klar gibts ne seite wo du kostenlos rt kurse von den amis bekommst.

[sneake]

aber ich wollt ja mein maul halten.frag doch goofy der hat bestimmt was.

[isoldefroehn]

leute wir sind doch nicht im Kindergarten oder
wir haben doch alle das gleiche Ziel

was die Realtime Kurse betrifft gib mir den Link oder lass es sein, wie du willst

Grüße

[GoofMan]

Sneake, vielleicht kannst Du es ja noch auf 20 weitere Beiträge aufteilen. Wenn Du lesen kannst, siehst Du unten ein Posting in dem ich sage das ich keine kostenlosen RT Kurse für USA kenne. Bisher habe ich die nicht gebraucht, da ich eh ein bezahltes RT System einsetze.

[hasi22]

heute Vortrag des CEO; wollte eigentlich auf einen dip warten, aber mir scheint derzeit gibts den kaum.

"They have a proven and PATENTED technology is that is in dire need in both the anti-viral efforts and bio-terrorism need. Market opportunities are limitless and they have patent protection...so whther they proceed to produce euipment or if they license rights...either way..they are gonna produce sweet revenues from this technology. Very smart on management to keep quiet until they got the EU patent!!!!!!
(Yahooboard)

daher, nachgekauft !

[GoofMan]

[posting]20.893.123 von hasi22 am 21.03.06 17:47:21[/posting]Ich hoffe er erwähnt bird flu scanner und staatliche Nachfrage nach solchen Geräten.

Immerhin sind auf dern Konferenz viele instituitionelle Anleger, wenn er es gut macht sollten wir bald einen Kursanstieg sehen. Ich weiss nichts obs morgen schon was wird, die Entscheidungswege sind bei FOnds etc ja teils ein wenig länger. Mittelfristig hoffe ich immer noch auf alte Höchststände.

[Tuttobene]

[posting]20.892.324 von GoofMan am 21.03.06 17:09:43[/posting]Kostenlose RT gibt es tatsächlich nicht.
Ich habe den Nordnet Trader, aber der kostet halt

[isoldefroehn]

[posting]20.893.169 von GoofMan am 21.03.06 17:49:52[/posting]Goofman

ich denke unser CEO wird wissen was er tut, da bin ich recht optimistisch nachdem ich einiges von Ihm gelesen habe

grüße

[sneake]

[posting]20.893.197 von Tuttobene am 21.03.06 17:51:22[/posting]doch gibt es.

[sneake]

[posting]20.893.123 von hasi22 am 21.03.06 17:47:21[/posting]hasi

wem gehoeren die patente dann wenn acacia geteilt wird?faellt das auf combimatrix?

[isoldefroehn]

nvax geht auch schon wieder auf die 8 $ zu

[sneake]

Dr. Amit Kumar Ph.D.

[hasi22]

[posting]20.893.246 von sneake am 21.03.06 17:54:05[/posting]sorry, weis leider auch nicht mehr.

Es gibt ja auch Pläne die Firma aufzuteilen;
- Forschung + Patente
- Produktion --> zahlt an Forschung

ist aber reine Spekultaion, und sollte uns m.E. nicht verunsichern, da wir bei einer Aufteilung Titel von beiden Firmen erhalten würden (so müsste es wenigstens sein).

[sneake]

[posting]20.893.356 von hasi22 am 21.03.06 17:59:43[/posting]mhh das macht mich nun aber schon etwas nervoes.

[Tuttobene]

[posting]20.893.456 von sneake am 21.03.06 18:04:16[/posting]braucht es aber denke ich nicht.

[GoofMan]

So um 20:20 Uhr geht die Übertragung los, bin ja mal gespannt.

http://www.wsw.com/webcast/in4/cbmx/

[sneake]

laeuft grad bei mir.aber geht noch nicht an.

[sneake]

mhhh nix.immer nur warteschleife.trinken die kaffee oder was.

[Tuttobene]

Habt ihr auch Generex gesehen

[sneake]

immer noch nix mit der übertragung.

[GoofMan]

Hm seltsam ja, mal schauen ob die wenigstens das Archiv mit der Übertragung nachträglich hochladen. Aber immerhin: Schluß über 2.50 US Dollar, also sollten wir morgen weiterhin brav über 2 Euro liegen

[sneake]

[sneake]

Last Sale: $ 2.59
Net Change: 0.23 9.75%
Share Volume: 2,523,799

[hasi22]

[posting]20.896.760 von Tuttobene am 21.03.06 20:52:34[/posting]Hallo Tutobene,
dieser wär`s also gewesen und nicht NVAX wie zuletzt im CMBX Board vermutet wurde.
Hab ihn leider auch nicht, aber ich denke bei CMBX sind wir für die Zukunft gut gerüstet.

[isoldefroehn]

die letzten Trades nachbörslich 2,63 $

jeden Tag die Perfomance und ich bin zufrieden

2.63 100 NSD 16:02:22
2.59 1300 NSD 16:01:32
2.59 1300 NSD 16:00:02
2.59 1011 NSD 15:59:58
2.58 1171 NSD 15:59:58
2.58 500 NSD 15:59:45
2.58 1000 NSD 15:59:44
2.58 1329 NSD 15:59:41
2.58 671 NSD 15:59:41
2.56 900 NSD 15:59:38
2.58 2000 NSD 15:59:37
2.58 1500 NSD 15:59:30
2.57 100 NSD 15:59:25
2.58 829 NSD 15:59:08
2.58 2171 NSD 15:59:08
2.57 500 NSD 15:59:08
2.56 140 NSD 15:58:52
2.56 19600 NSD 15:58:43
2.56 140 NSD 15:58:43
2.57 400 NSD 15:58:43
2.56 100 NSD 15:58:12
2.57 300 NSD 15:58:08
2.58 2500 NSD 15:57:55
2.58 200 NSD 15:57:49
2.58 300 NSD 15:57:49
2.58 5129 NSD 15:57:33
2.58 1000 NSD 15:57:30
2.58 1000 NSD 15:57:28
2.57 400 NSD 15:57:23
2.58 600 NSD 15:57:21

[isoldefroehn]

mal ne verständnisfrage haben die noch weiter aufgestockt?

#530 von sneake 20.03.06 22:53:49 Beitrag Nr.: 20.877.221
Dieses Posting: versenden | melden | drucken | Antwort schreiben

Index Components as of: 03/17/06

Merrill Lynch Nanotech Index - NNZ


Company Name Symbol % Weighting

Novavax Inc NVAX 4.57%
Nanogen Inc NGEN 4.47%
Acacia Research-Combimatrix CBMX 4.28%
Arrowhead Research ARWR 3.86%
pSivida Ltd. (ADS) PSDV 3.84%
Ultratech Inc UTEK 3.80%
Headwaters Inc. HW 3.75%
Harris & Harris Group Inc TINY 3.74%
Pharmacopeia Inc ACCL 3.73%
Westaim Corp WEDX 3.70%
Mts Systems MTSC 3.69%
Kopin Corp KOPN 3.68%
Amcol Intl ACO 3.67%
Nanophase Technologies NANX 3.65%
Cabot Corp CBT 3.65%
Veeco Instruments VECO 3.63%
Skyepharma Plc Ads SKYE 3.62%
Jmar Technologies JMAR 3.60%
Altair Nanotechnologies ALTI 3.54%
Immunicon Corp IMMC 3.53%
Symyx Technologies SMMX 3.52%
Nve Corp NVEC 3.48%
Tegal Corp TGAL 3.48%
Fei Co FEIC 3.42%
Biosante Pharmaceuticals BPA 3.39%
Lumera Corp LMRA 3.39%
Flamel Technologies Ads FLML 3.32%

Index Components as of: 03/20/06




Company Name Symbol % Weighting

Novavax Inc NVAX 5.11%
Acacia Research-Combimatrix CBMX 4.74%
Nanogen Inc NGEN 4.27%
Ultratech Inc UTEK 3.85%
Harris & Harris Group Inc TINY 3.83%
Arrowhead Research ARWR 3.81%
Pharmacopeia Inc ACCL 3.80%
pSivida Ltd. (ADS) PSDV 3.73%
Amcol Intl ACO 3.69%
Westaim Corp WEDX 3.69%
Headwaters Inc. HW 3.68%
Mts Systems MTSC 3.66%
Nanophase Technologies NANX 3.61%
Cabot Corp CBT 3.59%
Kopin Corp KOPN 3.59%
Veeco Instruments VECO 3.57%
Jmar Technologies JMAR 3.56%
Nve Corp NVEC 3.52%
Immunicon Corp IMMC 3.51%
Altair Nanotechnologies ALTI 3.48%
Skyepharma Plc Ads SKYE 3.47%
Tegal Corp TGAL 3.45%
Symyx Technologies SMMX 3.44%
Fei Co FEIC 3.40%
Biosante Pharmaceuticals BPA 3.35%
Lumera Corp LMRA 3.31%
Flamel Technologies Ads FLML 3.30%


oder hab ich da nen denkfehler drin?

[amok01]

[posting]20.898.564 von isoldefroehn am 21.03.06 22:38:16[/posting]Ich glaube schon.

Da der Kurs von Novavax und Acacia R. in den letzten Tagen sehr gut gestiegen ist und bei anderen Aktien im Portfolio gefallen ist verschiebt sich doch auch die Gewichtung oder sehe ich das falsch????????????

Na ja egal die Aktie wird sowieso Ihren Weg gehen und der sieht vielversprechend aus.

[Tuttobene]

[posting]20.898.352 von hasi22 am 21.03.06 22:24:12[/posting]Hi hasi,
ich Glücklicher habe am Montag und Dienstag in beide Titel, Acacia und Generex gut investiert.
Patriot hab ich dafür rausgehauen zum Glück.
Ich kann mir gut vorstellen, dass die beiden Werte noch gut Potential haben. Wenn erstmal die ersten toten Gänse in USA auftauchen gibt es kein Halten mehr

[whyso]

Tagesverlauf von CBMX gestern an der Nasdaq...



und das beste dabei:- After Hours kam ein weitere 4.25% Ansteig zustande, trading wurde "angehalten" bei $2.70...

Keep the faith, and the shares,
Whyso

[sneake]

[posting]20.899.280 von amok01 am 21.03.06 23:29:27[/posting]yup

[Nuno]

Danke Whyso, für den Tipp

[isoldefroehn]

Guten Morgen

Grüße

[isoldefroehn]

[posting]20.900.499 von whyso am 22.03.06 08:15:36[/posting]whyso

du schreibst "angehalten" wie darf ich das verstehen
???

Grüße

[janfer]

[posting]20.902.003 von isoldefroehn am 22.03.06 09:33:05[/posting]"Der Aktionär" hatte in der letzten Ausgabe die Combimatrix als Empfehlung beschrieben mit einem mittelfristigen Kursziel v. € 2,90. Die werden kommen. Offensichtlich müsste jedoch der Zeitkorridor neu definiert werden. Wenn das so weitergeht und auch nur eine einzige Meldung zu der Krankheit aus Amerika kommt, fliegt das Teil durch die Decke. Kommt immerhin von € 8,00 aus Anfang 2004. Bin gespannt wie lange es dauert, bis dass wir da wieder sind.

[Tuttobene]

[posting]20.902.187 von isoldefroehn am 22.03.06 09:39:55[/posting]Der meint die letzte nachbörsliche Kursfeststellung

[isoldefroehn]

[posting]20.902.523 von Tuttobene am 22.03.06 09:54:09[/posting]tutto danke

ich hatte es anders interpretiert, das zu 2,7 gehandelt wurde habe ich gesehen

Grüße

[Tuttobene]

[posting]20.903.383 von isoldefroehn am 22.03.06 10:27:52[/posting]Jetzt stehen in USA 4,89 im Brief.
Wenn die so eröffnen, dann ist der Teufel los

[Tuttobene]

Upsi, sorry das ist bei generex.

[whyso]

@isoldefroehn, "Angehalten"= vorrübergehend Pausierend >>>aber nur während die "Handelsstille Nachtrühe"

@Nuno, de Nada mein Freund..

Wir stehen hier m.E. am absoluten Anfang der CBMX Entwicklung...für unsichere kann ich ein Gespräch mit:
Bret L. Undem (Media Relations Combimatrix)
>>>001-425-493-2293 Fax: [phone]

wärmstens empfehlen, bei den herrscht kein stk.Euphorie im Gespräch, aber seine Aussagen sind sehr fundiert & weit blickend, hier sitzt ein sehr realistisch (nüchterne) aber aufbauende I.R. Mensch ...aber sein "Lob & Tadel" für die bisher geleistete Arbeit von Dr.Kumar,und auch für die neuen 90+ Array -(samt Diagnostics Markt)-kennt wiederrum keine Grenzen!!!

We are in on the ground floor, so mag ich Börse wirklich gern...

Good trades & steady hands,
Whyso

[sneake]

Bid: 2.30 x 100
Ask: 3.71 x 1100

[sneake]

was war mit dem interview gestern?

[GoofMan]

Das Interview ist hier verfügbar:

http://www.wsw.com/webcast/in4/cbmx/

[GoofMan]

Wichtige Info: Er hat die Vogelgrippe Pandemie erwähnt!! Siehe Folie 10!

[sneake]

[Tuttobene]

[posting]20.905.785 von sneake am 22.03.06 12:38:21[/posting]Wo hast du den Kurs denn her
Ich sehe 1,96 zu 2,70

[isoldefroehn]

news


March 22, 2006 - 7:01 AM EST

close Email this News Article
Your Name
Your Email
Friend`s Name
Friend`s Email
Receive Copy: yes

ACTG 7.96 -0.34

Today 5d 1m 3m 1y 5y 10y



CBMX 2.59 0.23

Today 5d 1m 3m 1y 5y 10y



Acacia Technologies Acquires Patents for Micromirror Digital Display Technology
Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) announced today that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has acquired a patent portfolio relating to the use of micromirrors to create a digital image in televisions, monitors, and projectors.

"As Acacia`s licensing success grows, more companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing as we continue to grow our base of future revenues by adding new patent portfolios," concluded Mr. Ryan.

The patented technology generally relates to techniques for using micromirrors to display a color image having gray scale gradations and is utilized in large screen televisions and projectors.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Acacia Research Corporation
Rob Stewart, 949-480-8300
Fax: [phone]



Source: Business Wire (March 22, 2006 - 7:01 AM EST)

News by QuoteMedia
www.quotemedia.com

[GoofMan]

Weitere wichtige Info aus dem Interview: CMBX redet mit verschiedenen Regierungen, incl. der USA, ausserdem mit der WHO über Einsatz der Technik zum Scannen gegen Vogelgrippe!!

[sneake]

http://translate.google.com/translate?u=http%3A%2F%2Fbiz.yah…

[sneake]

[posting]20.906.368 von Tuttobene am 22.03.06 13:15:58[/posting]http://finance.yahoo.com/q?s=CBMX

[isoldefroehn]

[posting]20.906.470 von GoofMan am 22.03.06 13:23:06[/posting]Nicht auszudenken wenn die einen Regierungsauftrag melden

dann aber

grüße

[Tuttobene]

Ich denke mal Acacia hab deutlich mehr Potential als Generex. Obwohl ich in beiden investiert und gut im Gewinn bin denke ich darüber nach, meine Gens in Acs zu drehen.

[GoofMan]

Eines scheint aber sicher: Mit smartem Trading (Limits!) wird keiner von uns mit dieser Aktie hier Geld verlieren. Das ist doch schon mal eine klasse Situation

[GoofMan]

[posting]20.906.708 von isoldefroehn am 22.03.06 13:40:20[/posting]Genau das ist meine Spekulation.

Szenario:

- Der erste tote Vogel mit Vogelgrippe wird in USA gefunden
- CNN pusht die Story (CNN live vor Ort: Bergung des armen Tierchens, Pandemie, blabla)
- US Regierung muss schnell einen Scanner herschaffen, um Entschlossenheit zu demonstrieren
- CMBX hat das Teil fertig rumstehen
- US Regierung kauft sich die Teile von
- Andere Regierungen sehen das und ziehen nach


Ist ein Gedankenspiel, aber kein abwegiges.

[Tuttobene]

[posting]20.906.851 von GoofMan am 22.03.06 13:49:36[/posting]Trading hier ist aber enorm gefährlich, denn eine tote Ente und das Teil explodiert.

[GoofMan]

[posting]20.907.082 von Tuttobene am 22.03.06 14:06:49[/posting]Stimmt, aber ich gehe immer davon aus das ich mich evtl irre und sicher ALLE Positionen ab. Es bietet sich evtl das free Share Prinzip an: Soviel verkaufen das man mit den restlichen Aktien sozusagen 0 Einstandspreis hat, dann kann man entspannen


Ach ja, USA gerade 2,81 prints, das wären 2,32 Euro hier

[Tuttobene]

[posting]20.907.183 von GoofMan am 22.03.06 14:12:48[/posting]und 2,31 haben wir schon

[GoofMan]

CNN.com von gestern:

(CNN) -- Detection of the highly pathogenic avian flu virus H5N1 inside the United States could come as early as this year, as government officials unveiled plans to increase monitoring and expand screening of migratory birds that could bring it.


http://www.cnn.com/2006/HEALTH/conditions/03/20/bird.flu/ind…


Super, die helfen unserer Aktie

[sneake]

http://www.rallymonkey.com/video/kenindex.swf

[Tuttobene]

[posting]20.907.478 von sneake am 22.03.06 14:31:12[/posting]

[GoofMan]

Info: Normalerweise kommen die ersten Zugvögel Ende Mätz / Anfang April in USA an. Würde mich sehr sehr wundern wenn da nicht einer mit Vogelgrippe bei ist.

[GoofMan]

Kleiner Tip noch: Auch STTK (US BB Stock, SMART-TEK SOLUTIONS) ist ein Vogelgrippe Trade. Allerdings viel riskanter als CBMX.

Ich habe momentan noch keine Position, schaus mir aber gerade mal genauer an.

[isoldefroehn]

[Tuttobene]

[posting]20.910.260 von isoldefroehn am 22.03.06 16:44:26[/posting]Kommt wieder

[sneake]

weiß schon jemand ab wann das insulin von cbmx zugelassen wird?

[sneake]

Antwort auf Beitrag Nr.: 20.914.573 von sneake am 22.03.06 20:33:38

keiner ???bin gleich als erstes raus und gleich in generex rein. mal abwarten was die amis heut treiben.

[Glück]

Antwort auf Beitrag Nr.: 20.915.760 von sneake am 23.03.06 09:18:51

Gibt´s irgendetwas Neues

[sneake]

Antwort auf Beitrag Nr.: 20.916.014 von Glück am 23.03.06 09:27:37

nein außer gestern die news.die steht ja hier drin.

[kafutznik]

Bid liegt in Amiland ganz schön tief komisch und Nachbörslich ging es auch noch in den Keller weiß einer warum

[sneake]

Antwort auf Beitrag Nr.: 20.917.936 von kafutznik am 23.03.06 10:49:26

war wohl großer ausverkauf gestern bei generex genauso.

[whyso]

Antwort auf Beitrag Nr.: 20.917.936 von kafutznik am 23.03.06 10:49:26

Tja, das klappt immer wieder mit die MM's an der Nasdaq...runter fahren kurz vor dem Schluss,( dann lassen sie die Europäer raten wo der Kurs hingeht Tagsüber) um dann das ganze kräftig hoch zu fahren circa 48 Std nachdem sie "unruhe" im kuts ausgestreut hatten...

Nee, nee ..mit mir nicht, ihr schlawiner

Sonnige Grüße,
Whyso

[hasi22]

Antwort auf Beitrag Nr.: 20.916.014 von Glück am 23.03.06 09:27:37

@Glück, du machst mich mit deinen Leeschlägen nicht glücklich (und viele Andere auch nicht) bitte um Verschonung

[hasi22]

Guten Morgen (heute etwas spät dran)

Bei Generex waren die Zahlen mit Verlust von 14 mio etwas negativ, immerhin haben sie noch fast 20 mio in der Bilanz.

Nun das eigenartige; bei CBMX sind auf Yahoo plötzlich die "Financials" ausgeblendet
dabei waren sie gar nicht so schlecht
(ist das wohl gezielt ?????)

[sneake]

NEWS !!!!!!!!!!!!!!!

Acacia Technologies Licenses Resource Scheduling Technology to Prophesy Transportation Solutions
Thursday March 23, 7:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 23, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that its Resource Scheduling Corporation subsidiary, which is part of its Acacia Technologies group, a leader in technology licensing, has entered into a license agreement with Prophesy Transportation Solutions, Inc., covering a patent that applies to systems for scheduling and managing resources. Prophesy Transportation Solutions, Inc. is a provider of software solutions for the Shipping and Transportation Industries.

The Resource Scheduling technology generally relates to methods and software application tools for scheduling and managing resources used in manufacturing facilities, hospital facilities, fleet delivery organizations, and other resource-dependent markets. These resource scheduling tools are often integrated as part of an Enterprise Resource Planning (ERP) solution used to manage a company's complete operations.

[Tuttobene]

Antwort auf Beitrag Nr.: 20.920.201 von sneake am 23.03.06 13:13:15

Aha, darum geht der Kurs gerade hoch

[sneake]

Antwort auf Beitrag Nr.: 20.920.263 von Tuttobene am 23.03.06 13:18:25

bin raus aus gene und rein in accacia mal sehen obs klappt heut.

[sneake]

na so richtig gehts noch ned hoch.

[sneake]

mnhhh die sind noch beim essen alle und haben die news noch gar ned gelssen.

[Tuttobene]

Bin mal auf der 2,16 raus, komme heute aber wieder, ich denke billiger

[sneake]

Antwort auf Beitrag Nr.: 20.921.063 von Tuttobene am 23.03.06 14:19:02

hast du rt gread da.meins spinnt

[Tuttobene]

Antwort auf Beitrag Nr.: 20.921.122 von sneake am 23.03.06 14:24:00

klar für dich immer: 2,40 zu 2,62

[sneake]

Antwort auf Beitrag Nr.: 20.921.149 von Tuttobene am 23.03.06 14:26:37

nee meint frankfurt

[Tuttobene]

2,1 ztu 2,13

[sneake]

Antwort auf Beitrag Nr.: 20.921.267 von Tuttobene am 23.03.06 14:34:51

danke.scheisse mein system spinnt.hab alles verzoegert.

[sneake]

Antwort auf Beitrag Nr.: 20.921.293 von sneake am 23.03.06 14:36:01

diese jahr soll ein insulin von cbmx zugelassen werden.weiss jemand ab wann das sein koennte?

[sneake]

man echt keiner mehr hier der schreiben tut???

[whyso]

Guten morgen zusammen!

Der springende Satz für die nächste Zeit bei CBMX

"Acacia will redeem all Acacia Research-CombiMatrix common stock for all the common stock of CombiMatrix Corporation, which will register its stock and plans to list its shares for trading on Nasdaq. Acacia expects the transaction to complete in the second quarter of 2006 subject to conditions. The deal is expected to benefit both companies by eliminating the risk factors associated with the current capital structure, Acacia said"


Diese Aktie-(und sein Marktplatz überhaupt)-wird erst noch Entdeckt, beim letzendliche "Analysten Erkenntniss" wird es dementsprechend stark steigende Kurse bei CBMX geben...

In for the long run,
Whyso

[sneake]

1 stunde und noch kein handel.

[hasi22]

komme eben erst an den Kompi.
Habe in einem anderen Forum etwas von Vogelgrippe in Brasilien gelesen , stimmt dies ?
herzlichen Dank und angenehmen Tag Hasi

[nort.]

Barchart steht auf vollem grün. Grüner geht es nicht mehr

http://quotes.barchart.com/texpert.asp?sym=cbmx

[hasi22]

Antwort auf Beitrag Nr.: 20.941.357 von nort. am 24.03.06 17:51:39

Darf ich mal den Frick slang anwenden;
"wird weiter steigen, ich würde kein Stück aus der Hand geben"
diesemal stimmts auch.
schönen Sonntag an Alle Hasi

[nort.]

CBMX im NNZ auf dem ersten Platz !

http://www.amex.com/?href=/othProd/prodInf/OpPiIndComp.jsp?P…


Acacia Research-Combimatrix CBMX 5.36%
Novavax Inc NVAX 4.58%
Nanogen Inc NGEN 4.18%
Arrowhead Research ARWR 4.11%

[sneake]

ACACIA RES-COMBIMATRIX - Nasdaq National Market: CBMX

Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time
3.10 0.54 (21.09) 0.42 (15.67) 12:13

[mikel_ann]

Antwort auf Beitrag Nr.: 20.953.176 von sneake am 26.03.06 20:52:56

Will nicht wirklich was heissen.

Aber da ist doch diese Woche die Konferenz in Indien !

CombiMatrix President and CEO Dr. Amit Kumar Invited to Speak at the International Knowledge Millennium Summit in India
Tuesday March 7, 7:00 am ET
Presentation Will Focus on CombiMatrix's Efforts in Bird Flu Surveillance and Cancer Diagnostics


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 7, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that Dr. Amit Kumar, President and CEO of CombiMatrix Corporation, will present an invited talk at the 4th Annual Knowledge Millennium Summit in India, on March 27th. This summit will focus on advances in biotechnology and nanotechnology, and includes participation from a group of international companies. This presentation will enable CombiMatrix to present its technology and products to the rapidly growing Indian and Asian Biotech and Nanotech communities as well as to participants from other countries.

[sneake]

Antwort auf Beitrag Nr.: 20.953.777 von mikel_ann am 26.03.06 22:59:20

das ist ja morgen schon:
mhh ich glaub ich behalte meine doch.

[sneake]

moren

erster kurs 2,32 bei 11000 umsatz super.

[sneake]

sorry meint 2,31

[whyso]

Antwort auf Beitrag Nr.: 20.953.777 von mikel_ann am 26.03.06 22:59:20

Yepp, da hast du recht, das Ereigniss wirft sein Schatten voraus



Die damalige Anstieg im fall NVAX, lässt uns mittlerweile auch bei CBMX herzlich grüßen
Good trades, but very steady hands,
Whyso

[sneake]

NEWS !!!!!!!!!!!!

Acacia Technologies Licenses Multi-Dimensional Bar Code Technology to Automatic Data Processing
Monday March 27, 7:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 27, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that VData, LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has entered into a license with Automatic Data Processing, Inc. ("ADP") covering a portfolio of patents that apply to certain multi-dimensional bar code systems. ADP is a market leader in providing shareholder communication for third parties in the form of proxy documents, account statements, stock trade confirmations, and related documents.

Many companies are beginning to adopt and utilize the new multi-dimensional bar code systems in their businesses," commented Paul Ryan, Chairman and CEO of Acacia. "The multi-dimensional bar codes have significant advantages over ordinary bar codes in sizing, accuracy, readability, and information capacity," concluded Mr. Ryan.

The multi-dimensional bar code technology generally relates to encoding and reading a data matrix consisting of an array of data cells with a border. The data matrix can contain a variety, amount, and depth of information that would not fit on to an ordinary bar code. This patented technology can have many applications in the manufacturing, distribution, accounting, and security industries such as tracking the movement of products, collection of data, improved production capabilities and anti-counterfeiting

[hasi22]

einfach unglaublich, praktisch jeden Tag eine zusätzliche technische Errungenschaft, die acquriert wird;
(aus Yahoo CBMX)

"• Acacia Technologies Licenses Multi-Dimensional Bar Code Technology to Automatic Data Processing
Business Wire (Mon 7:00am)

• Acacia Technologies Licenses Resource Scheduling Technology to Prophesy Transportation Solutions
Business Wire (Thu, Mar 23)

• Acacia Technologies Acquires Patents for Micromirror Digital Display Technology
Business Wire (Wed, Mar 22)

das machen die sicher nicht nur aus lauter Freude am Geldausgeben !

[smartcash]

Antwort auf Beitrag Nr.: 20.966.516 von hasi22 am 27.03.06 21:49:21

das betrifft doch den anderen Geschäftsbereich, nicht Combimatrix

[whyso]

Going places...

http://stockcharts.com/h-sc/ui?s=CBMX&p=D&yr=0&mn=4&dy=0&id=…

[ballack]

RT FFM: 2,26 €

[nort.]

INDIA und Tests:


Presence of live avian flu chain worrying: scientists
Wednesday March 29 2006 00:00 IST

IANS

BHOPAL: India may seem to have contained the spread of the bird flu, but scientists testing for the H5N1 virus say the presence of a live chain of the disease is worrying.

Researchers at the High Security Animal Disease Laboratory here say that many of the samples are unfit for testing as proper procedures were not followed for their collection and preservation.

"Most bird flu samples reaching us remain unfit for testing," H.K. Pradhan, head laboratory, told IANS. Several thousand samples, packed in iceboxes, arrive in the lab from various places.

"Many of the samples come in such a poor condition that it is not possible for the virus to be alive," he lamented.

The four samples that tested positive last week, he said, were from scattered domesticated population. "Though the samples showed the presence of the H5 virus, their N1 status could not been tested.

"But it is quite certain that they would have tested positive for N1 as well which means the virus is still in the environment and a direct link exists, as H5N1 cannot transmit without a live carrier," Pradhan said.

Culling and cordoning of affected zones - predominantly in Maharashtra - were done quickly enough to check the spread of the disease, he said. But the existence of a live bird chain is worrying.

"This live chain has to be broken as the disease is transmitted from bird to bird and not through air," he asserted.

"It is not possible to get a clear picture of the spread of the disease because proper procedures while collecting and preserving samples for testing are not followed.

"Many of the samples reaching us are in such a state that it becomes impossible to get a positive result even if they are infected."

Narrating the example of a sample that was so bad that scientists had to dump it in the incinerator without even opening it, Pradhan said: "A sample has to reach us when the virus is alive in the medium - dead chicken, blood, egg, tissue, or faecal matter - by maintaining a cold chain and sticking to the time of collection and packaging norms".

As for the culling procedure, Pradhan said, it is better to burn the carcasses.

"Buried animals can be dug out by dogs or jackals if the hole is not deep enough or they have not been treated properly with lime and chemicals," he said.

The lab is at present running out of time and space. While it can handle a maximum of about 2,000 blood samples and 100 tissue and faecal samples a week, it has been receiving 4,000 samples every week over the past month.

Six out of the eight rooms in the laboratory are now engaged in H5N1 work, distributed across a dozen scientists.

The pressure is forcing Pradhan and his colleagues to pick and choose samples.

"There is pressure," Pradhan admits, adding: "The top priority is for samples from sites with mortality."

[nort.]

http://biz.yahoo.com/bw/060328/20060328005855.html?.v=1

Acacia Technologies CEO Scheduled to Appear on CNBC
Tuesday March 28, 2:29 pm ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 28, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that the company's Chairman and CEO, Paul Ryan, is scheduled to be a featured guest on CNBC's "Squawk Box" on Wednesday, March 29, at 6:10 AM EST.

ADVERTISEMENT
A replay of the broadcast will be archived on the Acacia Technologies website www.acaciatechnologies.com.

Mr. Ryan's recent appearances on CNBC's "Street Signs" with Ron Insana on February 24, 2006 and CNBC's "Squawk Box" on March 6, 2006 are currently archived at www.acaciatechnologies.com.

The Acacia Technologies group partners with owners of patented technologies to license and enforce their patents.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

[hasi22]

hier eine Meinung aus Yahoo Board

currently UP 85 % in 1st qtr
by: mcvicar10 (38/M/Clearwater)
Long-Term Sentiment: Strong Buy 03/30/06 10:38 am
Msg: 29438 of 29440

Interesting to see where we close on Friday.

[mikel_ann]

Antwort auf Beitrag Nr.: 21.014.382 von hasi22 am 30.03.06 18:08:06

CombiMatrix Molecular Diagnostics Receives CLIA Certification
Friday March 31, 6:01 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 31, 2006--Acacia Research Corporation (NASDAQ:CBMX - News; NASDAQ:ACTG - News) announced today its CombiMatrix group's wholly-owned subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has received certification to operate as a clinical laboratory in accordance with the federal government's Clinical Laboratory Improvement Act (CLIA), a regulatory program that monitors the quality of laboratory testing. According to CLIA, any laboratory in the U.S. that conducts testing on human specimens for purposes other than research must be certified.
ADVERTISEMENT


"This is an important milestone for our company," said Matt Watson, CEO of CMDX. "Since opening our doors in May of 2005 we have been working diligently to establish a program of processes and procedures that would meet CLIA's strict quality control and quality assurance standards. Now that we have met those standards we are cleared to begin offering high quality clinical testing services at our state-of-the-art laboratory in Irvine, California."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG - News) and Acacia Research-CombiMatrix (NASDAQ:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[hasi22]

schau euch das mal an
sie eröffnen so eine Art Shops um ihre Produkte zu verkaufen

I just bought more at 2.60
CLIA-Certified
CMD alone is worth the price of admission
(I've waiting you this day for about a year)
it means
Cancer Diagnostics and Services
FDA Home-Brew status to make and run Genetic Tests In-house for clients
Big Pharma will send us business
Hospital & Doctors will send us business
US Govt will send us business
Above all it means
Baunoch & Watson & crew
have the GREEN light to "open up shop" and start making $$$$
new in town and wondering what the fuss is about:
the shop:
http://cmdiagnostics.com/
schaut das mal an !!!! sieht gut aus.

[hasi22]

auch das ist gut

6:04AM CombiMatrix recieves CLIA certification (CBMX) 2.57 : Co announces its CBMX group's wholly-owned subsidiary, CombiMatrix Molecular Diagnostics, has received certification to operate as a clinical laboratory in accordance with the federal government's Clinical Laboratory Improvement Act, a regulatory program that monitors the quality of laboratory testing. According to C.L.I.A, any laboratory in the U.S. that conducts testing on human specimens for purposes other than research must be certified.

(Babelfish transl.)
6:04AM CombiMatrix recieves CLIA Bescheinigung (CBMX) 2.57: Co verkündet vollständig-besessene Tochtergesellschaft seiner CBMX Gruppe, CombiMatrix molekulare Diagnose, hat empfangen Bescheinigung, um als klinisches Labor in Übereinstimmung mit der klinischen Tat verbesserung der Bundesregierung Labor, ein regelndes Programm zu funktionieren, das die Qualität des Laborversuchs überwacht. Entsprechend C.L.I.A muß jedes mögliches Labor in den VEREINIGTEN STAATEN, die die Prüfung auf menschlichen Probestücken auf Zwecke anders als Forschung leitet, bestätigt werden.

[hasi22]

Amis erwachen ja auch aus dem Winterschlaf,
bereits schöner Umsatz heute
gut Trade an Alle Hasi

[tom924]

schöner umsatz in dieser kurzen zeit! der positive markt könnte uns heute noch im plus halten, aber so langsam müßte sich wieder was rühren punkto...news oder adhoc...,sonst wird nicht mehr drinnen sein als eine seitwärtsbewegung.

[gehtsjetztendlich]

schaut euch auch mal ACTG an....
Seit vorgestern geht auch dort die Post ab

[ichwillsjetztwissen]

Antwort auf Beitrag Nr.: 21.056.196 von tom924 am 03.04.06 17:07:48

bin ich im falschen Film?
CBMX hauen doch eine News nach der anderen raus.
License Agreements mit:
Sony, Fujitsu am 31.03
Boston Scientific am 03.04

oder sprechen wir von unterschiedlichen Aktien?

[nort.]

Antwort auf Beitrag Nr.: 21.059.496 von ichwillsjetztwissen am 03.04.06 20:10:09

Nein ichwillsjetztwissen, Du bist genau richtig. Jemand setzt hier den Deckel drauf. Deck Dirch ein, trade ein wenig und schau zu, dass Du richtig aufgestellt bist, wenn es in den nächsten Level geht.

[sneake]

Antwort auf Beitrag Nr.: 21.059.496 von ichwillsjetztwissen am 03.04.06 20:10:09

die news betreffen nicht cbmx sondern deren bruder actg

[ichwillsjetztwissen]

Antwort auf Beitrag Nr.: 21.059.782 von sneake am 03.04.06 20:32:18

Da muss ich zugeben, habe ich ziemlich krass gepennt.
Bei Stockwatch sind die Meldungen bei CBMX (ACACIA RESEARCH-COMBIMATRIX) aufgetaucht. Als ich bei w:o nach der deutschen WKN von Acacia gesucht habe, bin ich hier gelandet.
ACACIA - ok das passt.
Da hab ich Paddel vermeintlich in den vollkommen verkehrten Wert investiert.

[RazorLux]

2.39 Dollar Anschnallen Leute !!!!

[gehtsjetztendlich]

also die news betreffen ausschließlich ACTG!!
Schlusskurs heute bei 10$ (+13%)

[nort.]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[DagobertDuck57]

ACACIA RES-COMBIMTRX (RT-ECN)
Symbol: CBMX
Last Trade: 2.27 9:58AM ET
After Hours Change: N/A
Today's Change: 0.12 (5.02%)
Bid: 2.26
Ask: 2.40

Hoffentlich gehts nicht unter 2 Dollar

[SirMarvel]

Was ist der Grund für den heutigen Kursverfall? ^^

[TimeFactor]

Antwort auf Beitrag Nr.: 21.070.626 von SirMarvel am 04.04.06 16:21:36

WKN:A0EAKE vielleicht ???

[hasi22]

Antwort auf Beitrag Nr.: 21.070.626 von SirMarvel am 04.04.06 16:21:36

Ich finde keine realen Gründe. Nach dem schönen Anstieg wird Kasse gemacht (oder man versucht Mitläufer raus zu drängen, siehe Karstadt kurz mal 15 % runter und jetzt geht's schon wieder rund)
ich bleibe investiert.

[RazorLux]

Mann, wir werden doch nicht wieder in einer Woche bei 1.75 Dollar stehen ... Ohne weitere News sieht's schlecht aus

[nort.]

Antwort auf Beitrag Nr.: 21.073.100 von RazorLux am 04.04.06 18:36:03

BUY ORDERS
SHARES PRICE
27,371 2.2900
27,671 within 5 cents
30,371 within 10 cents
As of 12:36:44.797

Order View Index
5.33
SELL ORDERS
SHARES PRICE
1,900 2.3100
7,031 within 5 cents
9,031 within 10 cents

[hasi22]

Hallo Leute,
ich glaube wir sitzen doch im richtigen Boot

"Unlike most tracking stocks,
the two from Acacia Research give investors 100% ownership.

In addition, by splitting itself into two trackers,
Acacia Technologies for its computer businesses and
CombiMatrix for its health care businesses.

trad:
"anders als die meisten aufspürenaktien, die zwei von Acacia Forschung Geben-InvestorBesitz 100%.
Zusätzlich durch das Aufspalten in zwei Verfolger, Acacia Technologien für seine Computergeschäfte und CombiMatrix für seine Gesundheitspflegegeschäfte, Acacia Forschung erlaubt Fonds-Geschäftsführungen, gerade im Teil des Geschäfts zu investieren, das sie sind interessiert innen."

http://www.usatoday.com/money/markets/us/2004-09-20-notrack_…

Noch zusätzlich die neusten Nachrichten in dieser Sache aus D.

[bubu]

... mir gefällt der Kursrücksetzer,
als Ex-Longie wäre ich ganz gerne wieder mit an Board.
Kauflimit steht bei roundabout 2 USD, jedoch in Deutschland.

Schaun mer mal.

Gruß
bubu

[hemj79]

Gibt es was Neues? Börse Stuttgart 1,91 zu 2,3!!!

[hemj79]

CombiMatrix Publishes Influenza Paper in Collaboration with World Health Organization (WHO) Laboratory after Filing Key Patent Applications
Thursday April 6, 6:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 6, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group paper describing the Influenza Surveillance technology has been published in the April edition of the Journal of Clinical Microbiology. This journal publishes the most-current research on microbiological aspects and diagnosis of human and animal infections and electronic versions of scientific publications can been accessed online at http://jcm.asm.org/current.dtl. The paper is titled "Use of Semiconductor-Based Oligonucleotide Microarrays for Influenza A Virus Subtype Identification and Sequencing." This research was conducted in collaboration with the U.S. Air Force Institute of Operational Health and the group of Dr. Richard J. Webby at the Infectious Diseases department of St. Jude Children's Research Hospital, chaired by Dr. Robert G. Webster.


CombiMatrix has previously applied for patents on its Influenza Surveillance technology. These patent applications were developed around and built upon CombiMatrix's microarray platform, processes, and instruments.

The CombiMatrix Influenza A Typing Microarray can identify all strains of Influenza A, including bird and human varieties. CombiMatrix's system, by tracking changes in genetic makeup of the virus, can differentiate highly pathogenic from less-lethal flu strains and can identify strains that may be resistant to drug therapy. In addition, this system can detect mixed or multiple infections of influenza. This has been identified as a critical issue for identifying infectious "carriers" of the disease, such as chickens that are able to infect others with the H5 virus but themselves have no symptoms. Information on such issues can be accessed at: http://www.cdc.gov/ncidod/EID/vol12no01/05-1024.htm.

[sneake]

schade irgendwie kommt das ding nicht von der stelle.

[DagobertDuck57]

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group President and Chief Operating Officer, Dr. Amit Kumar, will give a presentation on CombiMatrix's Electrochemical Surveillance System for Influenza and infectious diseases as well as a corporate overview at the Biotechnology Industry Organization's BIO 2006 Annual International Convention being held April 9th-12th, in Chicago, Illinois.

A live transmission of the presentation will take place at 12:15 p.m. CT on Wednesday, April 12, 2006. To access the live webcast please go to www.combimatrix.com/news_events.htm.

For more information about BIO 2006, please visit http://www.bio.org/events/2006/.



ABOUT ACACIA RESEARCH CORPORATION



Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:



This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[wiwifant]

CombiMatrix Molecular Diagnostics Establishes a Facility in the State-of-the-Art MaRS Discovery District in Toronto, Ontario, Canada



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 10, 2006--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group's wholly-owned subsidiary CombiMatrix Molecular Diagnostics (CMDX) has established a new facility in the world-class MaRS Discovery District in downtown Toronto.

"With the abundance of stellar scientists and research and clinical activities in and around the MaRS Discovery District and the fact that our Chief Scientific Officer and Vice President, Dr. Mansoor Mohammed, is a Canadian citizen, it was an easy and obvious choice for our expansion into the Canadian arena," said Dr. Amit Kumar, CEO of CombiMatrix. "Moving forward we anticipate establishing strong relationships with Canadian customers, partners and the government."

"Ontario's highly-skilled workforce, leading-edge research and proven ability to discover new ideas and turn them into innovative products is helping build a pervasive culture of innovation in our province," said Premier and Minister of Research and Innovation, Dalton McGuinty. "The MaRS Discovery District supports the discovery, funding and marketing of new ideas all in the same building. With its strong reputation for leading-edge research, CMDX is a welcome addition to this world-class facility."

Dr. Mohammed has been at the forefront of research and development in the fields of Comparative Genomic Hybridization (CGH) and microarray technologies for his entire professional career. Between 2001 and 2003 he produced the world's first commercially viable whole genome BAC array and co-authored one of its seminal clinical applications. He later directed the Advanced Technologies and Genomics program at Quest Diagnostics Inc, North America's largest commercial clinical laboratory. He is an internationally renowned scientist, speaker, and author and holds multiple patents in the fields of clinical genomics and microarray technology. "We are delighted to welcome Dr. Mohammed and CMDX to the MaRS Discovery District," said Dr. Ilse Treurnicht, MaRS CEO. "MaRS is dedicated to building a global gateway to Ontario research and innovation, and attracting world-class companies like CMDX is a critical component of our strategy."

"Toronto's vibrant medical and research institutions have long since demonstrated a strong track record for clinical trials initiatives with several of the world's leading pharmaceutical entities," added Dr. Mohammed, Chief Scientific Officer and Vice President of CMDX. "By placing our transformative genomic microarray technologies at the very epicenter of these activities, we anticipate creating a one-of-a-kind fusion between pharmacogenomic pursuits and genomics-based diagnostics. I am very excited to be involved in this expansion of CMDX and I am particularly proud to see its manifestation in Toronto. We anticipate drawing heavily from the exceptionally well-qualified researchers trained within the greater Toronto medical research community and I am eager to see to fruition the commercialization of novel, high value gene-based diagnostic products and services that I am certain will follow from our Canadian activities."

ABOUT MaRS

MaRS Discovery District (www.marsdd.com) is a not-for-profit corporation founded by leaders from the business and public sectors, to improve commercial outcomes from Canada's foundation of science and technology innovation. MaRS connects and fosters collaboration between the communities of science, business and capital through co-location in the MaRS Centre and more broadly through catalytic programs, structured networks and the MaRS web portal.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


CONTACT: Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: [phone]

SOURCE: Acacia Research Corporation

[schappi64]

Wer kann den Text übersetzen in Deutsch von Wiwifant

[simatic0815]

Antwort auf Beitrag Nr.: 21.144.521 von schappi64 am 10.04.06 15:03:51

Was ist nur los mit CMBX??? Wie weit fallen sie denn noch ??? Was ist der Anlaß dafür ???
Habt ihr info's???

[DagobertDuck57]

Klarer Kauf!!!
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…

[hasi22]

Guten Abend,
habe soeben CNN geschaut, wenn mich mein Englisch nicht täuscht, hat es leider in Mexico einen Todesfall eines kleinen Jungen infolge des Vogelgrippevirus gegeben!!

Im übrigen noch;
"I hope the Chicago Conference will be better received than Invest Northwest or the Conference in India. It depends on the speech of CEO Kumar. Is meat on the bone or not ?
If not it will be difficult to fight the selling pressure and prices below $2 will be seen again.

In just 48 hours we all know.


Alle wichtigen Indikatoren könnten nächstens wieder nach oben drehen

[simatic0815]

Antwort auf Beitrag Nr.: 21.148.775 von hasi22 am 10.04.06 18:31:25

Ich stehe vor der Frage ob ich nochmals kaufen soll oder nicht....!!!?? HELP ME PLEASE...

[ballack]

Antwort auf Beitrag Nr.: 21.149.389 von simatic0815 am 10.04.06 19:07:17

Nutze die Chance: Kaufen!

[TigerWutz I]

Antwort auf Beitrag Nr.: 21.149.389 von simatic0815 am 10.04.06 19:07:17

Nutze die Chance : WARTE AB !!

Du wirst doch nicht kaufen wollen, grad wo das Teil wie ein
Stein zur Erde geht. Warte bis es dreht und pfeif auf
die ersten 5- 10 % .

[hasi22]

Jezt bin ich wirklich gespannt wie selten mal, was die heutige Konferenz für Auswirkungen haben wird (vielleicht ja auch keine, da durch Insider immer alles schon eingepreist ist).

[hasi22]

hier eine sehr interessante Meldung
CBMX sieht sehr gut aus.

http://biz.yahoo.com/tm/060413/14188.html?.v=1

[DagobertDuck57]

Am 26.04 wirds interessant
http://www.combimatrix.com/docs/anfemail__apr06.pdf

[hasi22]

Habe noch die Insiderbestände angeschaut :

- Yahoo Anfangs März; % Held by Insiders4: 5.98%
- Meldung per 27.3.06; All Directors and Executive Officers as a Group (ten persons)(13) 3,117,992 7.5% (aller Shares)

N.b. Ryan, Harris und Kumar haben bisher pro Jahr je 90'000 Shares erhalten, also muss ein grosser Teil käuflich erworben sein.

wünschen Euch allen schöne Ostertage
Hasi

[whyso]

Die Spannung steigt-der Kurs nur minmal, das wird, das wird...


Hier ein paar "Links" mit den man rechnen kann...

http://www.fda.gov/OHRMS/DOCKETS/98fr/E6-5203.htm

http://www.pandemicflu.gov/


Kennt ihr den hier noch????
http://biz.yahoo.com/bw/060314/20060314005238.html?.v=1
Seine Name wird man öfters hören nach der bald kommende Split von Acacia

The spinoff is expected to be completed in the second quarter. CombiMatrix tracking shares will then convert to shares in the new company, which will be listed on the Nasdaq.



CBMX bleibt m.E. ein absoluten Strong Buy für den Zeitraum 2006-2008!
Good trades & steady hands,
Whyso

[sneake]

Acacia Research to Release First Quarter Financial Results and Host Conference Call
Monday April 17, 6:01 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 17, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today it will release its first quarter financial results on Thursday, April 20, 2006. Results will be released at the close of trading on the NASDAQ national market.

conference call is scheduled for the same day.

The Acacia Technologies Group presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern).

The CombiMatrix Group presentation and Q&A session will start at 2:00 p.m. Pacific Time (5:00 p.m. Eastern).

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers, both of whom will need to provide the operator with the confirmation code 3034242. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 3034242 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia's website at www.acaciaresearch.com.

[hasi22]

Hallo CBMX Freunde,

heute Nacht wird's sehr spannend !!!!!!!!!!!!!
die Resultate des 1. Q werden veröffentlicht.
Ich weiss auch nicht was zu erwarten ist, bleibe jedoch drin.

"EWPORT BEACH, Calif.--(BUSINESS WIRE)--April 17, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today it will release its first quarter financial results on Thursday, April 20, 2006. Results will be released at the close of trading on the NASDAQ national market.

A conference call is scheduled for the same day.

The Acacia Technologies Group presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern).

The CombiMatrix Group presentation and Q&A session will start at 2:00 p.m. Pacific Time (5:00 p.m. Eastern).

[smartcash]

Antwort auf Beitrag Nr.: 21.251.066 von hasi22 am 20.04.06 10:51:49

habe gerade dem Conference Call zum Quartalsergebnis zugehört.

Ein Rekordergebnis im Umsatz trotz des verspäteten Regierungsauftrages, es wurde zwar wieder beachtlich Cash gebraucht, aber es wurde auch sehr detalliert auf die Aussichten der neuen Produkte eingegangen, die in diesem Quartal gestartet sind. Die Auswirkungen auf den Umsatz schon für 2006 sollen sehr aussichtsreich sein. Die Erwartungen an den CMD-Bereich sind ebenfalls sehr gut, auch wenn man sich hier noch vorsichtig ausdrückt und nicht konkret wird.

Ein großer Teil des hohen Cashburns geht wohl auf die Vorbereitung der Trennung von Acacia Research bzw. dem eigenen Börsengang zurück und sind damit einmalige Kosten. (esp. legal costs)

Das Ergebnis wird die kurzfristigen Investoren eher zum Rückzug bewegen, die längerfristig denkenden werden dabeibleiben und ggf aufstocken.

Gruß
smartcash

[nort.]

Antwort auf Beitrag Nr.: 21.264.559 von smartcash am 20.04.06 23:34:47

gut zusammengefasst smartcash. Danke.

[hasi22]

Antwort auf Beitrag Nr.: 21.264.559 von smartcash am 20.04.06 23:34:47

besten Dank auch meinerseits; hier noch eine Meinung aus dem Yahooboard:

"Sorry to disappoint all the sellers
by: drchk2000
Long-Term Sentiment: Hold 04/21/06 01:14 am
Msg: 31765 of 31765

In the ECN the price was not changed, meaning - nothing happened, meaning - for this kind of stock - it will not crash. "

[hasi22]

Die Vorstellung der weiteren Geschäftsaussichten im Conferencecall waren offensichtlich überzeugend.

An der Vorbörse + 5.8 %%%%%%%%%%
(korrektur schon + 6.2 %)

Ich denke es kommt gut.

[nort.]

CombiMatrix Molecular Diagnostics Launches and Ships First Microarray Diagnostic Product Ahead of Schedule
4/21/2006 6:00:00 AM EST

BIOWIRE

Acacia Research Corporation (NASDAQ:CBMX) (NASDAQ:ACTG) announced today its CombiMatrix group's subsidiary CombiMatrix Molecular Diagnostics (CMDX) has begun shipment of its first diagnostic microarray product.

"This product, developed in conjunction with Array Genomics of France, has been designed to detect genomic copy number variations associated with constitutional chromosome imbalances as well as with those associated with over 40 defined genetic diseases and syndromes, such as DiGeorge and William's syndromes," said Dr. Mansoor Mohammed, CSO and Vice President of CMDX. "The more we learn about the heterogeneity with which specific genetic syndromes can be manifested, the more we begin to appreciate the need for array CGH in aiding more accurate differential diagnoses."

Roughly two thirds of patients, mostly children, who exhibit genetic developmental disorders are currently undiagnosed due to the lack of technology for such diagnosis. This inability to diagnose the underlying cause of the disorder makes it difficult to provide appropriate medication or useful genetic counseling. Our array, which can be used for pre- and post-natal analysis, will provide much greater genetic information for diagnosing and treating these disorders, than is available through conventional cytogenetic testing. This array is the first of several arrays in our pipeline that will help to enable the era of personalized medicine based on a genetic analysis of individual patients.

"We are pleased to have launched our first product ahead of schedule," stated Matt Watson, CEO of CMDX. "We began shipping this product to Europe this week. We will require FDA approval before we can sell the arrays for diagnostic applications in the U.S. This regulatory hurdle will not prevent us from selling the arrays domestically for research purposes, however. Also, now that we have achieved our CLIA certification, we will soon begin offering genetic testing services in our clinical laboratory. This quarter our clinical services will be based on this CGH array, and in the late third quarter of this year we will begin providing melanoma (skin cancer) diagnosis and typing services to our customers."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


http://www.genengnews.com/news/bnitem.aspx?name=632307

[DagobertDuck57]

Schaut mal hier rein
http://www.nasdaq.com/earnings/analyst_summary.asp?mode=&kin…

[nort.]

Antwort auf Beitrag Nr.: 21.278.237 von DagobertDuck57 am 21.04.06 20:39:32

dann mal auf zu den 5$

[nort.]

hat jemand im yahoo forum gut beobachtet:



50-MA schneidet 200-MA von unten. Dies ist eine Premiere bei CBMX und kann als Kaufsignal angesehen werden.

nort

[whyso]

Antwort auf Beitrag Nr.: 21.280.692 von nort. am 22.04.06 08:48:32

Echt lecker das ganze

Nur das Geld alleine zuhaus drücken zu können kommt besser als ein Investestion in CBMX zurzeit

"InPlay: CombiMatrix Molecular Diagnostics launches and ships first microarray diagnostic product ahead of schedule Briefing.com (Fri 6:06am) "

http://finance.yahoo.com/mp#cbmx

Viele grüße Nort & ein schönes Wochenende wünscht dir,
Whyso

[nort.]

http://www.ece.ucsb.edu/courses/ECE594/594F_F05Gossard/More%…


durchlesen

[nort.]

H5N1 Pandemic Level 4 Declared by Research Team Citing 23 Clusters and Case Histories





Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world.

(PRWEB) April 23, 2006 -- Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world. The combined effort focused on a three year period from 2003 to the 2006, listing 23 documented clusters of H2H. The report is based on millions of Internet searches and thousands of hours verifying data.

"Clusters of H5N1 infections," says one research member "They may indicate human to human transmission of H5N1 influenza or alternatively indicate common exposure to the virus from an environmental source, presumably avian. A cluster here is defined as two or more individuals: 1. Who are in close physical contact, 2. Who become very sick with a respiratory disease, and 3. at least one of whom is a confirmed H5N1 influenza case.

[hasi22]

Heute wieder gute Stimmung,

- steîgende Nachfrage nur zu höheren Preisen erfüllbar
- im Moment ein 10'000 Brocken im Bid
- Auftrag von der Army

"CombiMatrix Awarded Additional $1.9 Million Military Contract from the Army Research Office
Monday April 24, 6:00 am ET
New Contract an Addition to Existing CombiMatrix Contracts from the Department of Defense

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 24, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has received notification of a new award of $1.9 million from the Army Research Office. The contract will fund development of new products and capabilities for fielding CombiMatrix technologies."

[DagobertDuck57]

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group is collaborating with INBIO on the formation of a marketing and sales arm for Europe for CombiMatrix CustomArray(TM) products. The entity, "CombiMatrix Europe GmbH," is based in Freiburg, Germany. CombiMatrix Europe GmbH will begin by serving specifically Germany, the United Kingdom, Switzerland, and Austria. The new entity is making its first appearance at the Analytica 2006 conference currently underway in Munich.

"CombiMatrix's goal is to aggressively expand its marketing and sales through partnerships and distribution deals," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We already have distribution deals in place with INBIO and have been extremely pleased with their progress and expertise. CombiMatrix Europe expands this relationship to Europe, where CombiMatrix and INBIO see considerable opportunity and expansion."

"We are delighted to launch CombiMatrix Europe GmbH and anticipate a rapid uptake of CustomArray products within Europe. Importantly, our European customers will benefit significantly via the improved access to this unique microarray technology. The timing is perfect given recent and imminent advances in the capability of the CustomArray platform," said Mark Humble, CEO of INBIO.



ABOUT ACACIA RESEARCH CORPORATION



Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.



ABOUT INBIO



INBIO is the Life Science arm of BioInsight Pty Ltd and provides comprehensive distribution coverage for the Australian and New Zealand Life Science market for its international partners. INBIO's international expansion into Asia and Europe is providing the basis for strategic collaborations well beyond its initial foundation.

With a highly experienced commercial team, our focus is on providing innovative solutions for gene expression analysis. INBIO has formed distribution alliances with a range of organizations to satisfy our customers' demand for such products in this growing market segment. For more information on INBIO, visit our website at http://www.inbio.com.au.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:



This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[hasi22]

Es kommt alles Gut
in other News by: misc_info_06
Long-Term Sentiment: Strong Buy 04/26/06 10:20 am Msg: 32663 of 32664
"CombiMatrix's goal is to aggressively expand its marketing and sales through partnerships and distribution deals," said Dr. Amit Kumar
...
will begin by serving specifically Germany,
the United Kingdom, Switzerland, and Austria.

We are delighted to launch "CombiMatrix Europe GmbH"
and anticipate a rapid uptake of CustomArray products
within Europe.

The new entity is making its first appearance
at the Analytica 2006 conference currently underway in Munich.

[whyso]

WOW-es passt bei CBMX(vor die Trennung) langsam, aber doch sicher kriegt man "der Plan" mitgeteilt.



Das Chart spricht auch bände wenn man die folgende Zeilen vearbeitet bzw. positiv interpretiert hat:

"CombiMatrix's goal is to aggressively expand its marketing and sales through partnerships and distribution deals," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We already have distribution deals in place with INBIO and have been extremely pleased with their progress and expertise. CombiMatrix Europe expands this relationship to Europe, where CombiMatrix and INBIO see considerable opportunity and expansion."

"We are delighted to launch CombiMatrix Europe GmbH and anticipate a rapid uptake of CustomArray products within Europe. Importantly, our European customers will benefit significantly via the improved access to this unique microarray technology. The timing is perfect given recent and imminent advances in the capability of the CustomArray platform," said Mark Humble, CEO of INBIO.

http://biz.yahoo.com/bw/060426/20060426005218.html?.v=1

Hier Ensteht (m.E.) ein sehr kaufenswerte Story bzw. Firma mit vorne am GLOBALEN DIAGNOSTICS Markt von übermorgen!

Good trades y'all,
Whyso

[kafutznik]

CombiMatrix and Prisma Expand Relationship in China, Taiwan, and Other Countries
4/28/2006

NEWPORT BEACH, Calif., Apr 28, 2006 (BUSINESS WIRE) --
Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has entered a distribution and manufacturing agreement with Prisma Biotech Corporation. In this relationship, Prisma will promote and sell CombiMatrix products in Taiwan, China, and various other countries and, using CombiMatrix CustomArray(TM) Synthesizers in the region, has the ability to synthesize content onto CombiMatrix CustomArrays and to sell those arrays to end customers.

One of the strengths of CombiMatrix's platform is its CustomArray Desktop Synthesizer. CombiMatrix is now establishing manufacturing and distribution relationships with regional companies to enable them to manufacture arrays onsite for their local markets. Such relationships benefit CombiMatrix by expanding the commercial market for its products without having to build additional infrastructure. In addition to sales of synthesizers to the partner, CombiMatrix will continue to sell blank CustomArrays, reagents, additional synthesizers, and equipment to the partner for its local customers. CombiMatrix's partner benefits by gaining access to state-of-the-art microarray technology, which can then be manufactured locally. Other major array manufacturers are not able to execute this business strategy since their manufacturing methods do not enable distributed manufacturing.

"We are very pleased to have Prisma join CombiMatrix's growing international promotion and sales network," said Dr. Amit Kumar, President and CEO of CombiMatrix. "They are an aggressive sales organization, looking to expand their technology base. CombiMatrix sees great opportunity in the areas they serve and sees a great fit with Prisma's expertise."

"Prisma has a great deal of experience especially in the prevalent spotted-array market in Taiwan and China," said Kevin Tseng, President & CEO of Prisma Biotech. "Since we see CombiMatrix's CustomArray technology as the next stage in technological evolution over that technology, we were very interested in the ability to make it available. Users here have been calling out for the next wave. Now that we have it, we begin our work to expand the market and to provide the customers with this new technology."

ABOUT PRISMA BIOTECH CORPORATION

Prisma Biotech Corporation is a privately held company that was founded in 1995 in Taipei, Taiwan. Prisma has had over ten years of extensive expertise as a vendor and supplier of life-science-research and in vitro-diagnostic (IVD) products in Taiwan. In the area of life-science research, Prisma represents several major brand-name products in genomics and proteomics research, such as arrayers, laser scanners, high-throughput DNA analyzers, protein crystallography machines, automated liquid-handling workstations, and so on. In the area of IVD products, Prisma represents a number of worldwide leading products in lateral-flow technology-related biosensors, raw materials, consumables, accessories, and spotters.

Prisma's unique strength lies in its long-term experience in microarray-related products, which include arraying instruments, parts, accessories, hybridization reagents, and consumables. As a result, Prisma is very familiar with the products, market trends, and channels to the customers in both China and Taiwan.

Prisma is committed to delivering state-of-the-art, quality services and products in order to meet the customer's needs. For further information, contact Prisma at: 7th Floor, 72 Song-Te Road, Taipei 110, Taiwan; Tel: [phone], Fax: [phone]; Website: www.prismabiotech.com.tw.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

his news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Acacia Research Corporation

Acacia Research Corporation Bret L. Undem (Media Relations), 425-493-2293 Fax: [phone]

[hasi22]

Erste "milde" Voglegrippeerscheinung in den USA,
wobei dies meines Erachtens auf den Kurs nicht mehr der ausschlaggebende Faktor ist, sondern die sehr gute Entwicklungspipeline. Derzeit schönes Plus von 7 %

Long-Term Sentiment: Strong Buy 05/01/06 02:30 pm
Msg: 33134 of 33135
Mild form of avian flu found in New Jersey

May 1, 2006 — NEW YORK (Reuters) - Authorities have discovered a mild form of avian influenza at a live bird market in New Jersey, but it is not the deadly H5N1 strain governments around the world are trying to contain, the state's agriculture department said.

"The strain was found in a live bird market in Camden County. None of the birds in the market died from this virus, which is an indicator that the virus was low pathogenic and not harmful to humans," said a statement by New Jersey's Agriculture Secretary Charles Kuperus which was posted on Friday.

[kafutznik]

ACACIA RES-COMBIMATRIX Quick Quote: CBMX 2.22 (Even)




CombiMatrix to Collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on USA's National Early Detection System for Avian Influenza
5/2/2006

WADDL is One of Approximately 48 Labs in the U.S. That is
Certified for Influenza Testing

NEWPORT BEACH, Calif., May 02, 2006 (BUSINESS WIRE) --
Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group will collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on influenza testing. A broad interagency effort is being undertaken to monitor the Pacific Flyway, to determine if the seasonal migration of birds will bring the highly pathogenic Eurasian strain of Avian Influenza (AI: H5N1) into North America and the United States. This effort is being coordinated by the US Department of Agriculture, Department of the Interior, and the Department of Health and Human Services in collaboration with State regulatory agencies.

The Pacific Flyway includes Alaska, Western Canada, and the West Coast of the United States including Washington State. There is concern that the seasonal migration of birds will bring the pathogenic Eurasian H5N1 avian flu into this region of the world through the Pacific Flyway.

The current validated protocol for verification of a pathogenic influenza strain requires performing an initial PCR (polymerase chain reaction) to determine the existence of matrix protein gene, which is common to all Influenza A infections. If matrix protein is present, then a successive PCR for hemagglutinin is performed to determine if the H5 gene is also present. While this part of the procedure can be completed quickly, verification and further typing after a positive result requires that the sample be cultured and sequenced, necessitating roughly another week or more to complete. CombiMatrix's influenza monitoring system has shown in laboratory tests that it can confirm and type the infection in four hours. Our goal in this study is to demonstrate that our system produces quick virus typing results in the diagnostic laboratory environment that correlate to the standard protocol.

"Our Influenza Surveillance Technology has been validated in our laboratory in collaboration with the World Health Organization. We now seek to validate the system in the field in collaboration with WADDL," stated Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We are pleased that two Washington State organizations can function together to address this potential animal and public health concern."

"We look forward to working with CombiMatrix to determine if their technology can enable more rapid typing of influenza viruses from animals," said Dr. Terry McElwain, DVM, Ph.D., Professor and Executive Director of WADDL, and Director of Animal Health Research Center at the College of Veterinary Medicine, Washington State University. "While official verification of a highly pathogenic strain of influenza will require virus isolation initially, completing a test that can type the virus in four hours would be a significant advance over the conventional approach in monitoring spread of infection once an outbreak has been confirmed."

ABOUT WADDL

The Washington Animal Disease Diagnostic Laboratory (WADDL) is a publicly supported laboratory located in the College of Veterinary Medicine at Washington State University. With two locations in Pullman and Puyallup, the WADDL provides disease surveillance in animal, food, and environmental samples. WADDL was one of the 12 founding members of the National Animal Health Laboratory Network, and routinely performs diagnostic assays to detect disease agents such as avian influenza and BSE.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

his news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Acacia Research Corporation

Acacia Research Corporation Bret L. Undem (Media Relations), 425-493-2293 Fax: [phone]

Copyright Business Wire 2006

[whyso]

Watch ...die Amis werden langsam wach im sachen CBMX

Under 10$-no deal is possible with me!
Whyso

[whyso]

2,32 ist ein Platform, mehr auch nicht.

Nach der "Entdeckung" wird es "fast & furious" um die neue CBMX rum...

[nort.]

Antwort auf Beitrag Nr.: 21.410.646 von whyso am 02.05.06 23:00:39

Hallo whyso,

die 50-MA hält sicher und fest. Genauso wie früher bei NVAX Von mir aus können wir uns an dieser hochziehen.

nort

[GoofMan]

Hier eine interessante News, die gut zur Aktie passt. Hoffen wir, das CBMX im Gespräch ist, wenns ums Screening geht.

http://www.cnn.com/2006/HEALTH/conditions/05/03/us.birdflu/i…

[whyso]

Antwort auf Beitrag Nr.: 21.416.532 von GoofMan am 03.05.06 14:34:32

Good find GoofMan...

@Nort, ja genauso wie "damals"...

Sonnige Grüße,
Whyso

[nort.]

http://www.chron.com/disp/story.mpl/ap/world/3845300.html

May 6, 2006, 10:58AM
Nations Urged on Bird Flu Response Time

By MARGIE MASON AP Medical Writer
© 2006 The Associated Press

DANANG, Vietnam — Only half of the human bird flu cases detected by countries are being reported to the World Health Organization within two weeks _ a response time that must be improved to head off a potential flu pandemic, a senior WHO official said Saturday.

Dr. Shigeru Omi, the WHO's regional director for the Western Pacific, said it's estimated that two to three weeks is all countries would have to stamp out or at least slow a pandemic flu strain after it began spreading. He said the first move would be to identify cluster cases and report them to WHO. International teams would then be deployed to investigate the site, the area would be quarantined and antiviral treatment would be given.

"All the steps have to be done within two to three weeks. As of now ... even reporting the first step, it takes sometimes more than two weeks for half of the cases," Omi said at the end of an Asia-Pacific meeting on bird flu in central Vietnam. "There's a lot of challenges."

Omi said political commitment is now strong at national levels across the region, but weaknesses still exist in getting the message all the way down to villages. He said the level of public awareness must increase so that ordinary people will understand what to do if they see a number of people or poultry coming down sick at once.

Omi attended a meeting with agriculture and health ministers representing the 21-member Asia-Pacific Economic Cooperation. On Friday, they endorsed a plan aimed at stamping out bird flu and preparing for a potential flu pandemic.

Meanwhile, other delegates donned masks, goggles and biohazard suits Saturday morning as they toured a chicken farm in central Vietnam for a firsthand look at how hygiene is maintained.

"These countries have been dealing with avian influenza for several years and have clearly advanced thinking on it, so that's why I wanted to be here this morning to look at the activities that were successful here in Vietnam," said John Lange, the U.S. special representative for avian influenza. "They've been dealing with it and we're just expecting it."

Experts fear the H5N1 bird flu virus, which began ravaging Asian poultry stocks in late 2003, could mutate and potentially spark a global pandemic. The virus has killed at least 114 people worldwide, but most human cases have been linked to contact with infected birds.

The farm in Hoa Quy village in the coastal town of Danang had about 7,000 chickens, all of which had been vaccinated. Laying hens were kept in cages in an enclosed coop sprayed with disinfectant.

Much of the poultry in Vietnam and throughout Asia, however, is produced on a much smaller scale, with many households raising a handful of chickens in backyards. Such farming practices are much harder to control and make it easier for the H5N1 virus to spread.

A regional action plan adopted Friday calls for the restructuring of some backyard farming practices into larger, more controlled operations.

Officials said Australia will coordinate a regional practice exercise on June 7-8, with help from Singapore, to see how well countries respond and cooperate during a mock pandemic scenario.

[hasi22]

Hatte schon etwas Angst jedoch;

gmäss Thomson "Heavy Buying" in letzten Minuten

+ 11.5 %%%%%% im Moment

[nort.]

50-MA!!!

[nort.]

Percent Change
+15.38%
+5.26 (AH)

es geht weiter

[DagobertDuck57]

Wir sind auf dem richtigen Pferd
http://news.morningstar.com/news/BW/M05/D10/20060510005210.h…

[nort.]

Antwort auf Beitrag Nr.: 21.503.631 von DagobertDuck57 am 10.05.06 12:39:03

denken auch viele andere

BUY ORDERS
SHARES PRICE
1,700 2.2200
12,000 within 5 cents
12,000 within 10 cents
As of 13:36:55.353

Order View Index
5.25
SELL ORDERS
SHARES PRICE
600 2.2400
800 within 5 cents
900 within 10 cents

[DagobertDuck57]

Diesen interessanten Artikel sollte sich Jeder reinziehn!!!!!
Kursmanipulation und Gegenmaßnahmen,

...angenommen, du kaufst 1000 Aktien eines Stocks. der manipulative MM, der diesen Trade für dich ausführt, kann diese 1000 Aktien sofort leihen und bereits einen Trade später gegen dich einsetzen, indem er diese 1000 Aktien ins bid verkauft, also billiger. da die Umsätze erst nach 3 tagen gecovert werden müssen (also abgerechnet), kann der MM mit dem gesamten (kauf)Volumen ins bid gehen und somit eigentlich kaufwillige abhalten, weil die sich natürlich fragen " wer verkauft denn da zu diesen Schweinepreisen?" , was dazu führen kann, dass trotz guter News ein stock nicht steigt oder sogar fällt.

Wenn das von mehreren MM betrieben wird, ergibt sich im Handel ein verzerrtes bild der Realität. eigentlich ist der stock bereit zu steigen, wird aber dadurch das die Shares der Ask Käufer sofort wieder billiger ins Ask gegeben werden, im lauf ausgebremst und fällt sogar. dieses spiel kann diverse tage so gehen und die Anleger richtig Geld kaufen. viele verkaufen am gleichen tag oder spätestens nach 2-3 tagen entnervt ihre " fallenden" Aktien, was dazu führt, das der preis noch weiter fällt. Netter Nebeneffekt für die Shorts: bei fallenden Kursen sammeln sie links und rechts noch Stop Losses ein und die abends nach hause kommenden Shareholder fragen sich, wo ihre Aktien geblieben sind. flankiert wird dieses vorgehen oft von Bashern, die zuhauf in den Boards auftauchen und dort die Verunsicherung weiter schüren.

Nun wurde zum Jahreswechsel ja die SHO Regelung eingeführt, die die MM und Shorties zwingen sollte, nach 3 tagen zu covern, also geliehene Shares glattzustellen. was dann bedeutet hätte, das bei fundamental guten werten und standfesten Shareholdern die Shorties und MM reichlich Aktien hätten kaufen müssen, um die geliehenen wieder glattzustellen. das hätte zu extrem steigenden Kursen führen können (ein sogenannter Short Squeeze), weil bei theoretisch über 3 Tagen geliehenen und short verkauften 10 Millionen Aktien auch die gleiche menge Aktien hätte gekauft werden müssen -und das in der Regel aus dem Ask, was eben für einen fetten Rebound gesorgt hätte.

Da die MM und Hedges aber nicht doof sind, passiert nach dem drei tagen folgendes: der MM, der mit z. b. 50.000 Aktien short ist und nach Ablauf der 3 tage eigentlich covern müsste, leiht sich diese 50.000 Aktien von einem anderen MM, der nun wiederum 3 tage zeit hat, der verliehenen 50.000 Aktien zu covern. was dann passiert? richtig, MM Nummer 2 findet MM Nummer 3, der ihm erneut 50.000 " leiht" . dieses spiel kann unendlich fortgeführt werden, es könnte sogar der erste MM wieder 50.000 Aktien der Nummer 3 leihen, weil ja MM Nummer 1 durch MM Nummer zwei gecovert wurde.

und so kommt es, dass es reichlich werte auf der SHO liste gibt, die dort seit Wochen (was ja eigentlich unmöglich ist)stehen und aus diesem miesen Kreislauf nicht herauskommen und weiter fallen oder stagnieren.

einen teil der Opfer findest du hier:

http://www.nasdaqtrader.com/aspx/regsho.aspx

ganz pervers wird es beim nächsten punkt:
beim naked shorten wird oft auf Margin Basis gehandelt, das bedeutet, dass wenn du z.b. 1000 Aktien gekauft hast, diese zwischen 4- und 10-fach beliehen werden. mit jedem kauf von 1000 Aktien löst du also mögliche Verkäufe von 4000-10.000 Aktien aus. auch hier wird das covern - wie oben besprochen- durch gegenseitiges beleihen ausgebremst.

bei derzeit rund 8500 börsenwerten in den USA und existierenden 9000 Hedges fonds kannst du davon ausgehen, dass jede noch so gesunde Firma Opfer werden kann. dadurch werden milliardenwerte vernichtet und Kleinanleger um ihr Geld betrogen. die meisten short Attacken werden über Kanada, Offshore und (man vermutet das) über Berlin gefahren.

erst wenn die sec das gegenseitige covern unter den MM restriktiv verbietet und dieses auch konsequent umsetzt und Verstösse drastisch bestraft, wird sich daran etwas ändern. Aber diese mafiöse Allianz von Hedges, MM und großen Brokerhäusern hat eben nicht nur Finanzpower sondern auch politische Macht. auf jeden fall ist es der größte Beschiss des Jahrhunderts und er wird ganz offensichtlich geduldet von den wichtigen Herren der weltweiten Finanzmafia.

bei der SHO List geht es darum, das berüchtigte Naked Short Selling einzudämmen. Gesellschaften, deren Aktien die folgenden 3 Kriterien erfüllen, kommen jeweils am Handelstag auf die THreshold (SHO List).

~ There are aggregate fails to deliver at a registered clearing agency of 10,000 shares or more per security;
~ The level of fails is equal to at least one-half of one percent of the issuer?s total shares outstanding; and
~ The security is included on a list published by a self-regulatory organization (SRO).

A security ceases to be a threshold security if it does not exceed the specified level of fails for five consecutive settlement days

D.h. bei ca. 360 Mio. ausstehenden SHRN Aktien sind mind. 0,5% = 1,8 Mio. Aktien geshortet, ohne geliefert worden zu sein, d.h. naked short. Das ist seit mind. 7 Tagen der Fall und deswegen steht SHRN seit 2 Tagen auf der Liste. M.W. greift die SEC ein, wenn ein Wert eine gewisse Zeit auf der Liste steht (meine 13 Tage).

SHO List heißt also erstmal, es wird gedrückt (von 11 Cent auf knapp 8 Cent in den letzten Tagen, ohne zu liefern, d.h. MM geben Verkäufe ein, haben aber die Aktien nicht. Meistens gibt es einen kleinen Hype, wenn die SEC-Frist abläuft. Es kann aber auch sein, dass die neulich bei RB gemeldete Registrierung von 3,5 Mio. SHRN Aktien der Eindeckung der Naked Shorts dient, d.h. die Aktien sozusagen vorher verkauft wurden.

beim kiten werden deine gekauften shares sofort verliehen und ins bid geworfen.

du kaufst 5000 aktien aus dem ask (grüner umsatz). das war ein verkauf eines anderen, der von dir erworben wurde.

wenn das z.b. 20x passiert, steigt der kurs, weil das ask leergekauft wird und kaum etwas ins bid fliegt.

shorts kiten gemeinsam mit den market makern.

das heisst: zusätzlich zu den eh schon shorten aktien (also die permanenten 200er, 500er ticks ins bid) verleihen die MM in der gleichen sekunden deine aktien, also die 5000 grünen stücken und werfen sie ins bid zurück.

nun sind bereits 2x 5000 aktien verkauft und 1x gekauft worden. der kurs kommt nicht hoch sondern wird mit diesen aktionen nach unten gedrückt, weil das ask normalerweise schwächer wird und das bid dann ebenso weiter abfällt.

auf dem weg nach unten wird eingesammelt (wenn erste blöcke entnervter fliegen) und stop losses eingesammelt

anschliessend wir nach lust und laune entweder mit den billig abgegriffenen shares das geliehene volumen gecovert oder -was sie auch gerne machen (SHO liste): ein mm der 60.000 aktien short ist und nach 3 tagen ssettlen müsste,also covern, leiht sich einfach vom nächsten mm die 60k aktien, covert seine und ist durch damit. der andere market maker hat wieder 3 tage zeit und macht das gleiche nochmal.

so drehen sich also millionen geliehener aktien im market maker karussel und beeinflussen die kurse, obwohl es diese shares eigentlich nicht gibt.

einziges mittel wie erwähnt: schütze deine aktien, indem du einen verkaufsauftrag mit einem hohen verkaufspreis für deine aktie reinstellst, dann sind diese aktien zum beleihen gesperrt.

[nort.]

Antwort auf Beitrag Nr.: 21.542.051 von DagobertDuck57 am 12.05.06 19:29:50

schütze deine aktien, indem du einen verkaufsauftrag mit einem hohen verkaufspreis für deine aktie reinstellst, dann sind diese aktien zum beleihen gesperrt.

bei CBMX sollte dieser recht hoch sein. Man hat schon in der Vergangheitheit gesehen, dass eine quasi Verdoppelung schnell möglich ist

[whyso]

CNBC am 17 May ...three workdays and counting

und Rodman & Renshaw trommeln ab Montag
(wer errinert sich hier am der NVAX Entwicklung kurz nach der R&R Analyse???)

Schönes Wochenende ihr lieben,
Whyso

[nort.]

showtime is near?

BUY ORDERS
SHARES PRICE
1,800 2.0400
10,300 within 5 cents
11,300 within 10 cents
As of 15:01:26.528

Order View Index
9.44
SELL ORDERS
SHARES PRICE
90 2.0800
90 within 5 cents
90 within 10 cents

[nort.]

% Shares Owned: 10.6 # New Buyers: 9
# Institutions: 25 # Closed Positions: 6
Total Shares Held: 4,122,563 # Buyers: 15
3 Mo. Net Change: 1,134,710 # Sellers: 8
Price Range Quarter: $1.67 - $2.90 # Net Buyers: 7

http://today.reuters.com/stocks/InstHolders.aspx?ticker=CBMX

[nort.]

Canada ups effort to prepare for bird flu pandemic

http://in.today.reuters.com/news/newsArticle.aspx?type=world…

[nort.]

Ereignisse werfen ihre Schatten vorraus...

http://biz.yahoo.com/bw/060516/20060516006261.html?.v=1

Net Change
+0.2000
+0.1100 (AH)
Shares Matched
35,492
6,700 (AH)

Previous Close
2.0700
Percent Change
+9.66%
+5.09 (AH)

[nort.]

[kafutznik]

ACACIA RES-COMBIMATRIX Quick Quote: CBMX 2.16 (Even)




SAIC/EAI to Initiate Government Funded Influenza Screening Program with CombiMatrix Technology
5/17/2006

NEWPORT BEACH, Calif., May 17, 2006 (BUSINESS WIRE) --
Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group will collaborate with EAI Corporation, a subsidiary of Science Applications International Corporation (SAIC), for field deployment of CombiMatrix's influenza-screening technology for the identification of all versions of influenza A, including the highly pathogenic Eurasian (H5:N1) strain.

Funding for this program will be provided by the Center for Innovative Technology/Institute for Defense and Homeland Security through its Partnership Intermediary Agreement with the Department of Defense. Additional partners in this project include the San Francisco Bay Estuary Field Station of the US Geological Survey/Western Ecological Research Center and the Prince William Sound Science Center of Cordova, Alaska.

"The US government continues to be justifiably concerned about the entrance of highly pathogenic avian influenza into North America, and CombiMatrix continues to demonstrate the power of its technology in this realm," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "This collaboration with EAI gets our technology into the field and into the hands of people and groups standing watch on US soil. This program is in addition to our participation in the US Government's National Early Detection System."

"We are pleased that the Institute for Defense and Homeland Security has agreed to fund this combined effort with CombiMatrix," said Dr. Joe Dudley, Chief Scientist at EAI. "We believe that the CombiMatrix system is a powerful, versatile, and portable system for influenza monitoring. We believe that this approach, combined with EAI's mobile-laboratory products and expertise, will provide a very powerful tool for monitoring and preparedness in the event of a pandemic."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 43 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

ABOUT SAIC:

SAIC is the largest employee-owned research and engineering company in the United States, with more than 43,000 employees in over 150 cities worldwide. For the fiscal year ended January 31, 2006, the company reported annual revenues of $7.8 billion. SAIC engineers and scientists solve complex technical problems in national security, homeland security, energy, the environment, space, telecommunications, health care, and logistics. SAIC: FROM SCIENCE TO SOLUTIONS(TM). Additional information about SAIC is available at www.saic.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Acacia Research Corporation

Acacia Research Corporation Bret L. Undem (Media Relations), 425-493-2293 Fax: [phone]

Copyright Business Wire 2006

[hri]

kam grad ein interview bei CNBC
resultat vorb. 1.trade 1,51$

[whyso]

Antwort auf Beitrag Nr.: 21.620.916 von hri am 17.05.06 13:34:01

Pre-Market (RT-ECN): 2.58 0.42 (19.44%)

Only the beggining

[whyso]

Was für ein Satz

"The US government continues to be justifiably concerned about the entrance of highly pathogenic avian influenza into North America, and CombiMatrix continues to demonstrate the power of its technology in this realm," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "This collaboration with EAI gets our technology into the field and into the hands of people and groups standing watch on US soil. This program is in addition to our participation in the US Government\'s National Early Detection System."

Sexy Kumar, das ist echt Sexy Du hast wohl dazugelernt

[italy05]

Antwort auf Beitrag Nr.: 21.621.437 von whyso am 17.05.06 14:10:32

Ohja ,was für ein satz

Alle tage versinkt der Mist ins Bodenlose

[DagobertDuck57]

Antwort auf Beitrag Nr.: 21.642.059 von italy05 am 18.05.06 16:38:39

Das passiert nur wegen den nackischen Shortern Da gibt`s nur eines:N A C H K A U F E N!!

[nort.]

Antwort auf Beitrag Nr.: 21.642.059 von italy05 am 18.05.06 16:38:39

das GAP wurde zugemacht. Danach sollt es weitergehen



http://stockcharts.com/c-sc/sc?s=CBMX&p=D&yr=0&mn=6&dy=15&id…

[nort.]

Testing for Bird Flu Begins in Alaska

1 hour, 26 minutes ago

ANCHORAGE, Alaska - Federal scientists have started testing migratory birds for signs of a dangerous bird flu that could show up on this continent this spring.
ADVERTISEMENT

The testing of shorebirds began Wednesday on an Anchorage coastal wildlife refuge, said Bruce Woods, spokesman with the U.S. Fish and Wildlife Service.

It's the first sampling of a summer-long project to swab birds for bird flu throughout the state. Nationwide, the goal is to sample 75,000 to 100,000 wild birds. In Alaska, about $4 million in federal money will be allocated to study about 15,000 birds, Woods said.

"We had some success in catching some of the target species," Woods said Thursday.

More than 40 species of waterfowl and shorebirds are considered susceptible to infection by a highly pathogenic H5N1 bird flu virus that's killed more than 100 people, in other parts of the world, mostly in Asia.

Scientists will only test birds in the Anchorage area through early next week. "In this location, it's very brief, birds go through and their gone," he said.

To screen the birds for the deadly virus, the U.S. Fish and Wildlife Service and Alaska's Fish and Game Department also are setting up more than 50 remote backcountry camps accessible mainly by float planes or boats.

Many birds will be tested and released, while others killed during seasonal hunts will be tested after they have died.

Alaska is an ideal bird flu laboratory because it's at the crossroads of migratory pathways for birds flying between the United States and other countries. Some of these birds arrive in Alaska each year from Asia.

http://news.yahoo.com/s/ap/20060518/ap_on_sc/bird_flu_testin…

[nort.]

Canada to test 4,200 wild birds for avian flu
Thu May 18, 2006 2:25 PM EDT10

http://ca.today.reuters.com/news/newsArticle.aspx?type=domes…

[whyso]

CBMX NEWS 2006 >>>& Brean Murray sagt 12$ Voraus nach der Trennung von Acacia (Casherlöse müssen allerdings her) :

CombiMatrix group:

* In January 2006, the CombiMatrix group launched a series of catalog microarrays specifically designed for microRNA analysis. MicroRNAs ("miRNAs" ) are small, RNA molecules encoded in the genomes of plants and animals. These highly conserved, approximately 21-mer RNAs regulate the expression of genes and are believed to be critical to controlling physiology in areas that include neural development, viral disease, and cancer. Each miRNA is thought to regulate multiple genes, and since hundreds of miRNA genes are predicted to be present in higher eukaryotes the potential regulatory circuitry afforded by miRNAs is enormous. There is evidence that miRNAs may act as key regulators of processes as diverse as early development, cell proliferation and cell death, apoptosis and fat metabolism, and cell differentiation.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of Colorado Health Sciences Center under the Company's CombiCore(TM) access program. Under this agreement all University of Colorado researchers can purchase, through their microarray core facility, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the University of Colorado Health Science Center Microarray Core Facility.
* In January 2006, the CombiMatrix group entered into a non-exclusive distribution agreement with Cold Spring Biotech to distribute CombiMatrix products and services in mainland China, Taiwan, and Hong Kong. Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza A Research Microarray.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of California Davis under the Company's CombiCore(TM) access program. Under this agreement all University of California Davis researchers can purchase, through the UC Davis Genome Center, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the UC Davis Genome Center.
* In January 2006, the CombiMatrix group expanded its relationship with its existing partner, INBIO, for the Asia Pacific region. Major components of the expanded relationship include the transfer of day-to-day operational responsibility and majority ownership of CombiMatrix Corporation's wholly owned subsidiary, CombiMatrix K.K. (the "KK") to INBIO along with an expanded distribution agreement that encompasses Japan. INBIO obtained 67% of the voting interests in the KK and expanded its distribution agreements with the CombiMatrix group. INBIO assumed all operational and financial responsibilities of the KK including its liabilities.
* In January 2006, the CombiMatrix group announced that the 2006 U.S. Defense Appropriations Bill signed by President Bush included an allocation of $2.4 million to fund efforts by the CombiMatrix group to further develop its microarray technologies for the detection of biological and chemical threat agents.
* In February 2006, the CombiMatrix group began work on its one-year, $2.1 million contract with the US Department of Defense ("DoD" ). Funding for this contract, which focuses on the use of CombiMatrix' array technology for military and antiterrorist applications, was previously announced as part of the DoD budget. CombiMatrix's development program with the DoD is focused on the integration of CombiMatrix's biotechnology with microelectronics and microfluidics and the development of an automated system with maximum flexibility and sensitivity for biothreat agents with reduced size and cost.

In for the long run,
Whyso

[pes05]

Vogelgrippe
Neue Fälle in Rumänien

In Rumänien hat sich die Vogelgrippe weiter ausgebreitet. Mittlerweile ist in 34 Ortschaften das gefährliche H5N1-Virus bestätigt. In 24 weiteren Orten besteht Vogelgrippeverdacht. Das erklärte Landwirtschaftsminister Flutur im rumänischen Fernsehen.

Die Seuche ist auch bei Hühnern in einem Randviertel der Hauptstadt Bukarest nachgewiesen worden. Ein mehrere Straßenzüge großes Areal wurde unter Quarantäne gestellt, rund 300 Menschen dürfen das Viertel nicht mehr verlassen. Ein zweiter Verdachtsfall in einem anderem Viertel der Hauptstadt ist bisher vorerst nicht bestätigt. Beim Nachweis des Virus müssten dort nach Angaben der Behörden rund 13.000 Menschen unter Quarantäne gestellt werden.

Die Seuche war vor knapp zwei Wochen in zwei großen Geflügelbetrieben im siebenbürgischen Ort Codlea nahe der Kreisstadt Brasov ausgebrochen. Nach Angaben des Landwirtschaftsministeriums hat sich die Seuche vor allem deshalb weiter ausgebreitet, weil lebendes Geflügel aus Codlea unkontrolliert verkauft wurde.

Seit Ausbruch der Vogelgrippe im Oktober 2005 hat Rumänien nunmehr insgesamt 87 Infektionsherde gemeldet. Davon galten bis zum 21. April 53 für beseitigt, nachdem dort alles Geflügel getötet worden war.

[DagobertDuck57]

Seeeeeehr guuuut, weiter so

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has signed a subcontract with Northrop Grumman (NYSE:NOC) to develop technology and components for the Handheld Isothermal Silver Standard Sensor (HISSS) program. The Special Project Office of the Defense Advanced Research Projects Agency (DARPA) funds the HISSS program. More information can be obtained on the HISSS program by visiting their website at http://www.darpa.mil/spo/programs/hisss.htm.

The goal of the HISSS program is to develop a handheld sensor that is capable of identifying biological weapon threats across the entire threat spectrum including bacteria, viruses and toxins. The HISSS sensor will be based on isothermal technologies that hold the promise of allowing silver-standard quality identification in a small, low-logistics package.

Financial support for this work will be provided through Northrop Grumman's contract. Should this contract expand into Phase IV and eventually into procurement, CombiMatrix may be awarded additional contracts to develop technology and supply components.

"We look forward to building a long-term successful relationship with Northrop Grumman," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Our technologies and capabilities span a very wide spectrum and this subcontract enables us to provide our microfluidics capabilities to Northrop Grumman."



ABOUT NORTHROP GRUMMAN CORPORATION



Northrop Grumman Corporation provides products, services, and solutions in information and services, aerospace, electronics, and shipbuilding to the military, government, and commercial customers in the United States and internationally. The company provides airborne radar, navigation systems, electronic countermeasures, precision weapons, airspace management systems, space systems, marine and naval systems, communications systems, government systems, and logistics services. It also designs nuclear-powered aircraft carriers and nuclear-powered submarines, as well as provides services for various naval and commercial vessels. The company also offers design, engineering, construction, and life cycle support; and network-enabled integrated systems and subsystems for U.S. government, civil, and international customers. It also supports the military with intelligence, surveillance, and reconnaissance; battle management command and control; and integrated strike warfare. In addition, the company integrates command, control, and intelligence systems; missile systems; strategic missiles; missile and air defense; airborne reconnaissance; intelligence management and processing; electro-magnetic and infrared analysis; communications; and decision support systems, as well as delivers life-cycle solutions for information systems and services; C4ISR; strategic security; engineering and science; training and simulation; base and range operations; and enterprise information technology solutions and products. Further, it develops and integrates spacecraft systems and subsystems, electronic and communications payloads, avionics systems, and laser systems and subsystems. The company was founded in 1939 and is headquartered in Los Angeles, California. More information is available at http://www.northropgrumman.com.



ABOUT ACACIA RESEARCH CORPORATION



Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 44 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:



This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[swissalps]

Hallo hasi22! Dieses Gegenmittel ist einwandfrei,wird sich bewähren und etablieren. Die VOGELGRIPPE wird uns jahrelang beschäftigen, denn sie schlummert genauso wie AIDS in Gebieten, die es punkto Hygiene nicht so ernst nehmen!

[whyso]

Antwort auf Beitrag Nr.: 21.756.026 von DagobertDuck57 am 23.05.06 14:02:51

Hi Dagobert,

Northrop Grumman das ist in der Tat ein richtig "Sexy scalp" für CBMX ...

Jetzt werden ganz andere Zeitgenossen zweimal hinschauen,
Long & strong,
Whyso

[italy05]

Hallo

U wiso tümpelt der kurs dann Monate lang vor sich hin

weis das jemand??

[DagobertDuck57]

ACACIA RES-COMBIMTRX (RT-ECN)
Symbol: CBMX
Last Trade: 1.98 4:00PM ET
After Hours Change: N/A
Today's Change: 0.05 (2.46%)
Bid: 1.79
Ask: 2.13

Bei solchem Preis grenzt es schon an Dummheit, wenn man nicht Nachkauft

[hri]

hier die meldung von bloomberg zu indonesien, scheint alle vogelgrippeaktien wie HEB, GNBT und CBMX nachb. anzuheben :

Top Worldwide



Seven Indonesian Bird Flu Cases Linked to Patients (Update1)
May 23 (Bloomberg) -- All seven people infected with bird flu in a cluster of Indonesian cases can be linked to other patients, according to disease trackers investigating possible human-to-human transmission of the H5N1 virus.

A team of international experts has been unable to find animals that might have infected the people, the World Health Organization said in a statement today. In one case, a 10-year- old boy who caught the virus from his aunt may have passed it to his father, the first time officials have seen evidence of a three-person chain of infection, an agency spokeswoman said. Six of the seven people have died.

Almost all of the 218 cases of H5N1 infections confirmed by the WHO since late 2003 can be traced to direct contact with sick or dead birds. Strong evidence of human-to-human transmission may prompt the global health agency to convene a panel of experts and consider raising the pandemic alert level, said Maria Cheng, an agency spokeswoman.

``Considering the evidence and the size of the cluster, it\'s a possibility,\'\' Cheng said in a telephone interview. ``It depends on what we\'re dealing with in Indonesia. It\'s an evolving situation.\'\'

The 32-year-old father in the cluster of cases on the island of Sumatra was ``closely involved in caring for his son, and this contact is considered a possible source of infection,\'\' The WHO said in its statement. Three others, including the sole survivor in the group, spent a night in a ``small\'\' room with the boy\'s aunt, who later died and was buried before health officials could conduct tests for the H5N1 virus.

`Directly Linked\'

``All confirmed cases in the cluster can be directly linked to close and prolonged exposure to a patient during a phase of severe illness,\'\' the WHO said.

While investigators have been unable to rule out human-to- human transmission in the Sumatran cluster, they continue to search for other explanations for how the infections arose, the WHO statement said.

Health experts are concerned that if H5N1 gains the ability to spread easily among people, it may set off a lethal global outbreak of flu. While some flu pandemics are relatively mild, the 1918 Spanish flu pandemic killed an estimated 50 million people worldwide.

So far, studies of the Sumatran outbreak and genetic analyses of the virus don\'t indicate the virus has undergone major changes, Cheng said. Scientists at WHO-affiliated labs in the U.S. and Hong Kong found no evidence that the Indonesian strain of H5N1 has gained genes from pigs or humans that might change its power or spreading ability, WHO said.

Mutations

``These viruses mutate all the time and it\'s difficult to know what the mutations mean,\'\' Cheng said.

Health officials earlier found strong evidence of direct human-to-human spread of H5N1 in Thailand in 2004. Scientists reported in the Jan. 27, 2005, issue of the New England Journal of Medicine that the H5N1 virus probably spread from an 11-year- old girl in Thailand to her aunt and mother, killing the mother and daughter. People who had more casual contact with the girl didn\'t become infected.

In the Sumatran cluster, close, direct contact with a severely ill person was also needed for spread, Cheng said. Preliminary findings from the investigation indicate that the woman who died, considered to be the initial case, was coughing frequently while the three others spent the night in the same room. One of the three, a second brother, is the sole survivor. The other two, her sons, died.

``It looks like the same behavior pattern\'\' of close contact and caretaking during illness with the bird flu virus, Cheng said. To raise the level of pandemic alert ``it would have to be transmissible from more casual contact.\'\'

General Community

The Indonesian Ministry of Health and international scientists are continuing their investigation to trace the origins of the infections, the WHO said in its statement.

``Priority is now being given to the search for additional cases of influenza-like illness in other family members, close contacts, and the general community,\'\' the WHO said. ``To date, the investigation has found no evidence of spread within the general community and no evidence that efficient human-to-human transmission has occurred.\'\'



To contact the reporter on this story:
John Lauerman in Boston at [e-mail].
Last Updated: May 23, 2006 14:46 EDT

[whyso]

Nice afterhours action (sowie bei NVAX)

ACACIA RES-COMBIMTRX (RT-ECN)
Symbol: CBMX
Last Trade: 2.19 5:11PM ET
After Hours Change: 0.19 (9.50%)
Today's Change: 0.16 (7.88%)
Bid: 2.13
Ask: 2.24

@hri, ich hoffe der "Vogel" (bei dir auf den Arm) hat CBMX's test bereits hinter sich gebracht?!?

[hri]

Antwort auf Beitrag Nr.: 21.766.997 von whyso am 23.05.06 23:30:58

na weiß nicht aber das war vor 4 jahren im südam. dschungel, da ich heut nix hab, hatte der wohl auch nix.

[nort.]

Avian influenza – situation in Indonesia – update 14

23 May 2006

The Ministry of Health in Indonesia has confirmed an additional case of human infection with the H5N1 avian influenza virus. The case occurred in a 32-year-old man. He developed symptoms on 15 May and died on 22 May.

The case is part of a family cluster in the Kubu Sembelang village, Karo District, of North Sumatra. The man is the seventh member of an extended family to become infected with the H5N1 virus and the sixth to die. An additional person, who was the first member of the family to fall ill, died of respiratory disease on 4 May. No specimens were taken prior to her burial and the cause of her death cannot be determined. However, as her clinical course was compatible with H5N1 infection, epidemiologists at the outbreak site include this woman as the initial case in the cluster.

The newly confirmed case is a brother of the initial case. Specimens were taken on 21 May and flown the same day to Jakarta. Tests run overnight confirmed his infection. His 10-year-old son died of H5N1 infection on 13 May. The father was closely involved in caring for his son, and this contact is considered a possible source of infection.

Although the investigation is continuing, preliminary findings indicate that three of the confirmed cases spent the night of 29 April in a small room together with the initial case at a time when she was symptomatic and coughing frequently. These cases include the woman’s two sons and a second brother, aged 25 years, who is the sole surviving case among infected members of this family. Other infected family members lived in adjacent homes.

All confirmed cases in the cluster can be directly linked to close and prolonged exposure to a patient during a phase of severe illness. Although human-to-human transmission cannot be ruled out, the search for a possible alternative source of exposure is continuing.

Both the Ministry of Health and WHO are concerned about the situation in Kubu Sembelang and have intensified investigation and response activities. Priority is now being given to the search for additional cases of influenza-like illness in other family members, close contacts, and the general community. To date, the investigation has found no evidence of spread within the general community and no evidence that efficient human-to-human transmission has occurred.

Analysis of viruses

Full genetic sequencing of two viruses isolated from cases in this cluster has been completed by WHO H5 reference laboratories in Hong Kong and the USA. Sequencing of all eight gene segments found no evidence of genetic reassortment with human or pig influenza viruses and no evidence of significant mutations. The viruses showed no mutations associated with resistance to the neuraminidase inhibitors, including oseltamivir (Tamiflu).

The human viruses from this cluster are genetically similar to viruses isolated from poultry in North Sumatra during a previous outbreak.

[nort.]

Vogelgrippe: Tausende in Bukarest unter Quarantäne
Maßnahme gilt für bis zu drei Wochen

Nach der Bestätigung eines Vogelgrippe-Falles sind mehr als 13.000 Bewohner der rumänischen Hauptstadt Bukarest unter Quarantäne gestellt worden. Die Maßnahme gelte für einen Zeitraum von ein bis drei Wochen, sagte der Bürgermeister des südlich gelegenen vierten Bezirks, Adrian Inimaroiu. Alle Geschäfte und Behörden in dem Viertel blieben in dieser Zeit geschlossen. Etwa 2500 Vögel in der Gegend würden so schnell wie möglich getötet.

Polizisten und Soldaten sperrten die Zugangsstraßen ab. Das rumänische Landwirtschaftsministerium hatte zuvor bestätigt, dass in der Region das Virus in mehreren toten Hühnern gefunden worden sei. Am Sonntagabend war bereits eine Gegend in den nördlichen Vorstädten von Bukarest unter Quarantäne gestellt worden. In den vergangenen zehn Tagen waren laut Landwirtschaftsministerium 38 Vogelgrippe-Fälle in Rumänien festgestellt worden. In 26 weiteren Fällen ist das Virus noch nicht offiziell bestätigt.

http://www.mittelbayerische.de/SID_2e0c1c48ab2ded70267a7c08f…

[hri]

news :

Press Release Source: Acacia Research Corporation


Acacia Technologies Licenses Interstitial Internet Advertising Technology to aQuantive, Inc.
Wednesday May 24, 6:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--May 24, 2006--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that InternetAd Systems, LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has entered into a license agreement with aQuantive, Inc., covering a patent that applies to interstitial Internet advertising.

[1000kV]

News, News, eine dumme News nach der anderen
und im Kurs geht nichts voran!!!!
Ich will endlich einen steigenden Kurs,
diese Drecksnews gehn mir langsam aufen Sack

[nort.]

Antwort auf Beitrag Nr.: 21.776.389 von hri am 24.05.06 12:28:30

falsche Baustelle...

[gehtsjetztendlich]

@1000KV
und wieder jemand ohne wirkliche Ahnung....
Diese Meldungen beziehen sich auf ACTG und nicht auf CBMX

Alles klar?!

[nort.]

Video

http://www.combimatrix.com/news_komo050906.htm

[nort.]

Antwort auf Beitrag Nr.: 21.785.623 von gehtsjetztendlich am 24.05.06 20:00:06

wird wirklich Zeit für den Spin of von ACTG...

[1000kV]

Antwort auf Beitrag Nr.: 21.785.623 von gehtsjetztendlich am 24.05.06 20:00:06

...dat weiß ich auch, soviel läßt mein Englisch zu!
Es bezieht sich auf diese Aktie und sollte
den inneren Wert pos. beeinflussenTut es aber leider nicht

[nort.]

The death of six members of the same family has raised fears that bird flu is spreading from person to person.

http://www.dailymail.co.uk/pages/live/articles/news/news.htm…

[nort.]

WHO Statistik

http://www.who.int/csr/disease/avian_influenza/country/cases…

[DagobertDuck57]

Hallo Mädels,schon die Herztabletten eingenommen???
Bei solchen Kursen wird Morgen nochmal groooß eingekauft

[nort.]

CDC !

Experts from around the world are watching the H5N1 situation very closely and are preparing for the possibility that the virus may begin to spread more easily from person to person.

http://www.cdc.gov/flu/avian/outbreaks/current.htm#backgroun…

[whyso]

Antwort auf Beitrag Nr.: 21.806.699 von nort. am 26.05.06 11:19:02

Hi Nort...where did you find that

[nort.]

Antwort auf Beitrag Nr.: 21.806.957 von whyso am 26.05.06 11:28:03

beim "Markführer"

[nort.]

jetzt sollte das bessere Halbjahr für Bios anstehen...



Also einsteigen und laufen lassen

nort

[nort.]

Renowned Genomics Expert, Stephen W. Scherer, Joins CombiMatrix Molecular Diagnostics' Science Advisory Board

http://biz.yahoo.com/bw/060531/20060531005254.html?.v=2

Dr. Stephen W. Scherer
by: misc_info_06 06/01/06 01:09 pm
Msg: 36158 of 36165

Understanding the composition of the human genome for studies of genetic disease.

Recent work characterizes structural variation in the human genome,
and examines the role genetics has in autism.

Long-standing endeavors include the study of human chromosome 7
as a model of the chromosomal basis of disease, and

building genomics infrastructure to facilitate biomedical research.

http://www.tcag.ca/scherer/


Awards

2005/2006 GlaxoSmithKline Endowed Chair in Human Genetics and Genomics (to be awarded spring of 2006)
2005 10th Anniversary Distinguished Achievement Award in Health Sciences, Canada's Top 40 Under 40
2004 Steacie Prize Award in the Natural Sciences
2003-2008 Canadian Institutes of Health Research (CIHR) Investigator Award
2002-2007 Howard Hughes Medical Institute International Scholar Award
2002 Genetics Society of Canada Young Scientist Award
2002 The Canadian Institute for Advanced Research (CIAR) Young Explorer's Prize
2001 International Year of the Volunteer Recipient, The Hospital for Sick Children Foundation
2001 Burroughs-Wellcome Visiting Professorship in the Basic Sciences (Visiting Professor to Memorial University, St. John's Newfoundland)
2001 Honorary Degree from the University of Windsor for contributions to genetics, genomics and public education
2000 Canada's Top 40 Under 40 AwardTM for Contributions to Society
1999-2002 Premier's Research Excellence Award

... many more

http://www.tcag.ca/scherer/awards.html


first microarrays for mental abnormalities, now an "autism expert"

kind of looks like CMD is targeting a market.

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[italy05]

man bin ich Blöd u hab die scheisse nicht verkauft

[italy05]

wohin laufen lassen ?? in den abgrund??

[schappi64]

was ist denn heute hier los?absturz warum welche nachrichten.

[nort.]

so ab jetzt wird es wieder spannend...

[italy05]

Ja spanned

So heist es schon ein jahr lang,du hast doch geschrieben?,anfang 2006 ist der kurs auf 10 dollar,oder irre ich mich?

[nort.]

Antwort auf Beitrag Nr.: 22.036.475 von italy05 am 10.06.06 09:17:38

Lieber italy,

ich bezweifle, dass ich terminierte zweistellige Kursziele von wenigen Monaten propagiert habe. Ich bin immer noch der Meinung, dass diese Aktie auf dem aktuellen Level günstig bewertet ist und eine positive Zukunft vor sich hat/haben kann.

Man muss allerdings sagen, dass Du in diesem Board seit Okt/Nov 05 herumjammerst und eigentlich ausser roten Smileys kaum etwas zur Diskussion beiträgst. Wenn Deine Gier so groß war, dass Du diese Sch**aktie (Zitat Italy) beim letzten Anstieg nicht verkauft hast, dann musst Du DIR selbst Vorwürfe machen. Aber sehe es positiv, jetzt kommen wieder Kaufkurse und der nächste Anstieg ist so gut wie vorprogrammiert

nort

[italy05]

ich hasse halt mal wenn man von 10 Dollar (Kann ja sein das du das nicht warst) spricht,denn davon ist man Lichtjahre endfernt

Wenn ich neuigkeiten von der Firma weis stell ich die auch rein, aber wenn ich nur vermutungen habe ,(wie viele anderen) halte ich die Klappe

ciao

[nort.]

Antwort auf Beitrag Nr.: 22.038.845 von italy05 am 10.06.06 13:14:20

Börse == Spekulation == Vermutungen...

Klappe halten ist eigentlich nicht typisch für Italiener...

[italy05]

wer sagt das ich Italiener bin??

Man sollte nicht gleich mit 10 Dollar Kleckern,das meinte ich mit Klappe

[nort.]

ublished: Sunday, June 11, 2006

Local firms join in bird flu battle

By Eric Fetters
Herald Writer


Those battling to head off a possible bird flu pandemic include local biotechnology companies who are developing testing tools and potential treatments.

In Mukilteo, CombiMatrix Corp. has used its electrochemical detection technology for a flu test that can identify specific strains, including H5N1, within hours instead of days. The test is set to be tested outside the lab by the Washington Animal Disease Diagnostic Laboratory at Washington State University in Pullman.

Last week, CombiMatrix representatives also attended a joint meeting organized of the U.S. Department of Agriculture and the Department of Homeland Security that focused on the threat posed by bird flu and other diseases.

CombiMatrix's chief executive officer, Amit Kumar, and David Danley, the company's director of homeland security and defense programs, told the meeting about how its technology can be used to help monitor for such diseases.

Meanwhile, Nastech Pharmaceutical Co. in Bothell has experimented with using small interfering RNA, which has shown the potential to combat production of flu viruses, as a possible treatment. In the company's in vitro tests, it recorded "highly potent" results against human and bird flu strains.



http://www.heraldnet.com/stories/06/06/11/100bus_fluside001.…

[DagobertDuck57]

Guckst Du hier
www.isanh.com/avian-influenza

[wiwifant]

Hallo zusammen, ich glaube hier einen Grund für die Kursentwicklung der letzten Wochen, bei niedrigen Umsätzen gefunden zu haben. Hier wurde der versucht dem Finanzierungspartner ein ansprechendes Einstiegsniveau zu bieten. Sehr positiv ist die Sicherung der Entwicklungskosten für die nächsten 2 Jahre. also eventuell eine gute Nachkaufgelegenheit.

CombiMatrix Announces $50 Million Equity Financing Commitment



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--June 15, 2006--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that it has executed a standby equity distribution agreement for up to $50 million in common stock equity financing from Cornell Capital Partners, LP ("Cornell") for its CombiMatrix group. Subject to the terms and conditions of the agreement between Acacia Research Corporation and Cornell, over the next 24 months, Acacia may sell registered shares of its AR-CombiMatrix common stock at its discretion to Cornell at a 2.5% discount from the market price. The shares of common stock are being offered pursuant to an effective registration statement filed with the SEC on April 25, 2006.

"This funding structure provides us the flexibility to access additional capital at our discretion," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "This commitment will enable us to finance the company for the next two years, during which time we hope to become the leading company in molecular diagnostics."

[whyso]

Very good news for CBMX



Alpha Innotech and CombiMatrix Diagnostics Combine Products in a Marketing Agreement

SAN LEANDRO, Calif.--(BUSINESS WIRE)--June 15, 2006--Alpha Innotech Corp. (OTCBB:APNO - News), a leading provider of bioanalytical systems for drug discovery and life science research, today announced a marketing agreement with CombiMatrix Molecular Diagnostics (CMDX) to mutually promote and distribute an integrated analysis solution for Comparative Genomic Hybridization. The agreement is centered on the synergies between Alpha Innotech's AlphaScan® laser scanner and CMDX's Comparative Genomic Hybridization (CGH) arrays for neonatal screening and biomarker discovery. As part of the deal, CombiMatrix Molecular Diagnostics will integrate Alpha Innotech's AlphaScan® scanner into its CGH platform. Financial terms were not disclosed.

Sia Ghazvini, Vice President of Business Development at Alpha Innotech, said "We are pleased to be working with CombiMatrix Molecular Diagnostics to provide this integrated solution for customers performing CGH analysis. We believe customers will appreciate a turnkey solution that combines DNA content, a reader, analysis software, and a validated laboratory protocol into a single integrated package. We intend to continue partnering with leading application developers like CMDX to provide best-of-class, application-focused integrated solutions for their customers."

"Our customers are looking for a single integrated platform that will enable them to quickly set up a CGH laboratory and begin running experiments," said Matt Watson, CEO of CMDX. "Alpha Innotech's AlphaScan® scanner represents a key component of that platform and we are excited to be able to offer it as part of our turnkey solution."

http://biz.yahoo.com/bw/060615/20060615005770.html?.v=1

Das könnte so ein Art "Initialzündung" (mit die Finanzierungsnews) mit sich bringen!

Steady Hands,
Whyso

[nort.]

Gentleman, H5N1 könnte in Amerika angekommen sein...

Samstag, 17. Juni 2006
Hausgeflügel in Ungarn infiziert
Vogelgrippe erreicht Kanada

In Kanada ist ein Gänseküken mit Vogelgrippe diagnostiziert worden. Bisher ist noch nicht ermittelt, ob es sich bei dem Erreger um das tödliche H5N1-Virus handelt. Die Zeitung "Globe and Mail" berichtete, dass das erkrankte Tier in einer kleinen Geflügelzucht in der Provinz Prince Edward Island auffiel.

Nach dem Bericht weist bisher nichts darauf hin, dass das H5N1-Virus nun auch nach Nordamerika vorgedrungen ist. Die kanadische Lebensmittelaufsicht erinnerte daran, dass Vögel und Geflügel in Massen sterben, wenn sie mit H5N1 in Kontakt kommen. Das treffe in diesem Fall nicht zu. Der gefürchtete H5N1-Stamm des Vogelgrippe-Erregers hat sich bisher auf 48 Länder ausgebreitet.

In Ungarn ist das für den Menschen gefährliche Vogelgrippe-Virus H5N1 unterdessen erstmals bei Hausgeflügel aufgetreten. Die in der vergangenen Woche in einem landwirtschaftlichen Betrieb im südungarischen Kiskunmajsa erkrankten Zuchtgänse wurden vom H5N1-Erreger befallen, berichtete der ungarische Rundfunk unter Berufung auf die aus dem EU-Referenzlabor in London eingetroffenen Untersuchungsergebnisse.

Ungarn brauche keine zusätzlichen Maßnahmen zu ergreifen, sagte Oberstveterinär Miklos Süth. Die Behörden hätten bereits beim ersten Auftreten des Vogelgrippe-Verdachts in Kiskunmajsa so gehandelt, als seien die Tiererkrankungen vom H5N1-Untertyp hervorgerufen worden. Unter anderem waren in der Umgebung des betroffenen Landwirtschaftsbetriebs 440.000 Hühner, Enten und Gänse gekeult und Sperrzonen eingerichtet worden. In Ungarn hatte das H5N1-Virus bislang nur Wildvögel befallen.

[nort.]

Vogelgrippe: Erste Ansteckung unter Menschen erwiesen
zurück
Der gefährliche Vogelgrippe-Erreger H5N1 ist während der Übertragung innerhalb einer indonesischen Familie mutiert. Das ergab eine Untersuchung der Weltgesundheitsorganisation (WHO).

http://www.orf.at/?href=http%3A%2F%2Fwww.orf.at%2Fticker%2F2…

[whyso]

Antwort auf Beitrag Nr.: 22.250.768 von nort. am 23.06.06 18:14:45

Yepp und das "Echo" davon wird bei CBMX demnächst erst ersichtlich...

Ahead of the Bell: Bird Flu Biotechs
Thursday June 22, 9:25 am ET
Biotechs Developing Bird Flu Products Set to Open Up As WHO Reports Likely Contagious Case

NEW YORK (AP) -- Shares of biotech companies developing products to fight bird flu were set to open up Thursday after the World Health Organization concluded the virus was likely transmitted person-to-person in Indonesia recently

http://biz.yahoo.com/ap/060622/ahead_of_the_bell_bird_flu.ht…

[nort.]

BUY ORDERS
SHARES PRICE
200 1.5300
10,900 within 5 cents
10,900 within 10 cents
As of 15:17:22.792

Order View Index
8.06
SELL ORDERS
SHARES PRICE
100 1.5500
200 within 5 cents
400 within 10 cents
Terms of Use

[nort.]

Severe avian flu outbreak could claim 1.9 million lives

http://www.dailyherald.com/news/illinoisstory.asp?id=203584

[whyso]

USDA RELEASES 180-DAY REPORT ON AVIAN INFLUENZA EFFORTS
AND SUPPLEMENTAL SPENDING

WASHINGTON, June 29, 2006 - The U.S. Department of Agriculture today released
its 180-day report on avian influenza (AI) efforts and the use
of $91 million appropriated in the Emergency Supplemental Appropriation
to Address Pandemic Influenza six months ago. The report details USDA's efforts
both internationally and domestically to combat highly pathogenic H5N1 avian influenza (HPAI H5N1).

"We're working with federal and state government partners,
as well as industry to prepare the public for the possibility
of a highly pathogenic avian influenza detection in the United States,"
said Agriculture Deputy Secretary Chuck Conner.

[nort.]

Avian influenza – epidemiology of human H5N1 cases reported to WHO

30 June 2006

This week’s issue of the Weekly Epidemiological Record, published online by WHO, sets out results from the first analysis of epidemiological data on all 205 laboratory-confirmed H5N1 cases officially reported to WHO by onset date from December 2003 to 30 April 2006.

Data used in the analysis were collected for surveillance purposes. Quality, reliability and format were not consistent across data from different countries. Despite this limitation, several conclusions could be reached.

* The number of new countries reporting human cases increased from 4 to 9 after October 2005, following the geographical extension of outbreaks among avian populations.
* Half of the cases occurred in people under the age of 20 years; 90% of cases occurred in people under the age of 40 years.
* The overall case-fatality rate was 56%. Case fatality was high in all age groups but was highest in persons aged 10 to 39 years.
* The case-fatality profile by age group differs from that seen in seasonal influenza, where mortality is highest in the elderly.
* The overall case-fatality rate was highest in 2004 (73%), followed by 63% to date in 2006, and 43% in 2005.
* Assessment of mortality rates and the time intervals between symptom onset and hospitalization and between symptom onset and death suggests that the illness pattern has not changed substantially during the three years.
* Cases have occurred all year round. However, the incidence of human cases peaked, in each of the three years in which cases have occurred, during the period roughly corresponding to winter and spring in the northern hemisphere. If this pattern continues, an upsurge in cases could be anticipated starting in late 2006 or early 2007.

A more standardized collection of epidemiological data by countries and timely sharing of these data are needed to improve monitoring of the situation, risk assessment, and the management of H5N1 patients.


http://www.who.int/csr/don/2006_06_30/en/index.html

[nort.]

WHO Warns Against Bird Flu Mutation

June 30, 2006 1:52 p.m. EST

Nji Che - All Headline News Staff Writer

Geneva, Switzerland (AHN) - The World Health Organization (WHO) on Friday warned against the risk of bird flu mutation into a form that could easily be transmitted from human-to-human. The UN health agency added that there could be more cases of human infection by the end of the year.

According to a report that analyzed 200 known bird flu cases, there have been three phases of human infection since the first one was reported in 2003. All the phases were witnessed during spring and winter in the northern hemisphere.

The document says, "If this pattern continues, an upsurge in cases could be anticipated starting in late 2006 or early 2007."

It adds that, "Moreover, the widespread distribution of the H5N1 virus in poultry and the continued exposure of humans suggest that the risk of virus evolving into a more transmissible agent in humans remains high."

The WHO says the analysis of the bird flu infection pattern is similar to that witnessed in the 1918-1919 Spanish flu outbreak. The epidemic claimed more than 40 million lives across the globe.


http://www.birdflubreakingnews.com/templates/birdflu/window.…

[hri]

vorb. gibts mehrere news !

[buyer10]

Hallo zusammen,
bin normalerweise nur stiller Mitleser. Durch den Kursverlauf gen Süden bin ich aber doch ein wenig verunsichert.
Vor allem wen man die Entwicklung von Acacia Res. zu Acacia Tech. vergleicht. Hier hat Tech. doch wesentlich besser performt als die Res!
Schön langsam glaub ich, hab ich aufs falsche Pferd gesetzt.
Dass der Gesamtmarkt momentan sehr volatil ist, ist schon klar.
Vielleicht habe die Experten hier in diesem Thread ja eine Ahnung was los ist.
Für eine Antwort wäre ich sehr dankbar
Noch schöne Grüsse an alle Investierten

[wiwifant]

CombiMatrix and Furuno Launch DNA Microarray Synthesizer; New CE Marked Instrument Incorporates Reagents and Arrays in a Single Stand-Alone Unit



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--July 13, 2006--Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) announced today that its CombiMatrix group, working in partnership with Furuno Electric Co., Ltd. of Japan, has launched its new QuadroCAS(TM) CustomArray(TM) Synthesizer. Jointly designed and developed by the two companies, this new instrument integrates CombiMatrix's proprietary electrochemical in situ oligonucleotide synthesis technology into a compact, stand-alone design.

Manufactured by Furuno at their instrument production facility in Japan, the QuadroCAS Synthesizer combines convenient and reliable reagent handling hardware with state of the art Furuno instrument control and signal processing electronics to deliver a full-featured, small footprint instrument for CustomArray production applications. Designed and tested to meet appropriate safety certification standards, the QuadroCAS Synthesizer will bear the CE ("European Conformity") and TUV markings (i.e., tested by TUV to meet the minimum requirements of prescribed product safety standards) and is suitable for worldwide distribution. Using this instrument, researchers around the world will be able to rapidly produce custom DNA microarrays to their exact specifications with complete control over the content.

Hidetoshi Tanigaki, Managing Director and General Manager of Furuno, said, "We are excited about the launch of the new QuadroCAS DNA Microarray Synthesizer. This instrument represents an important new product line for the life-science business group at Furuno."

"The QuadroCAS Synthesizer expands our synthesis product line," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "We look forward to offering our customers this dynamic enabling instrument."

The QuadroCAS Synthesizer fabricates CombiMatrix CustomArray microarrays that contain thousands of microelectrodes that are individually addressable using embedded logic circuitry on the microarray. Placed in one of four specially designed fluidic chambers, the system software digitally directs the molecular assembly of oligonucleotides for each separate array. During this process thousands of different oligonucleotide probes can be synthesized simultaneously on four different individual arrays.

Features on the new QuadroCAS Synthesizer include:

-- The QuadroCAS Synthesizer, along with the CombiMatrix
CustomArray Synthesizer(TM), are the only commercially
available DNA microarray synthesizer instruments in the
marketplace, providing high quality in situ fabricated arrays
on demand.

-- The QuadroCAS Synthesizer fabricates up to 4 high quality in
situ arrays simultaneously with the same or unique probe
designs in 24 hours or less, depending on the array format of
the experiments run.

-- The QuadroCAS Synthesizer allows the flexibility to design
each probe sequence to the exact specification of the user for
any organism and allows customers complete control over
inventory for on-demand in situ microarrays.

-- The QuadroCAS Synthesizer has a compact footprint and
incorporates all reagents and hardware into a stand-alone
instrument.

-- The QuadroCAS Synthesizer will be certified by TUV to be
compliant to EU directive IEC61010-1 73/23/EEC and 89/336/EEC
with the latest amendments 92/31/EEC and 93/68/EEC.

More information on the CombiMatrix QuadroCAS Synthesizer and other CombiMatrix instruments may be found on the CombiMatrix website -- www.combimatrix.com.

ABOUT FURUNO

Furuno Electric Co. Ltd. (Hyogo, Japan) has built a firm position as the world's leading manufacturer of innovative marine electronic equipment. Since Furuno put the world's first fish finder into practical use in 1948, Furuno has been steadily expanding its activities to cover a wider range of market sectors. Now, Furuno applies its sophisticated electric, ultrasonic and computer technologies to avionic equipment, marine radar, sonar, and navigation systems, GPS survey systems, data management devices for office and store automation and medical electronic equipment.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 47 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


CONTACT: Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: [phone]

[TigerWutz I]

52-WochenTief !!
Das muss man erst mal schaffen. Respekt.

[italy05]

diesr Mist fällt ins bodenlose

[Achates]

Antwort auf Beitrag Nr.: 22.430.864 von buyer10 am 06.07.06 10:56:53

Kann nur sagen mir geht es genau so!

[whyso]

Mein Yahoo Ansicht der CBMX Lage:
------------------------
This war isn't lost by a longshot-it hasn't even started, thats the point!

MOLECULAR DIAGNOSTICS will be the road to travel in 2007, the question is does Kumar fly our plane, or do we need an experienced pilot who knows the course without a navigations system and can demonstrate same to a still "ignorant marketplace"?

CBMX's potential is awesome, but only with the RIGHT leadership

[nort.]

[gerdass]

Antwort auf Beitrag Nr.: 18.317.787 von hasi22 am 17.10.05 21:01:18

[wiwifant]

News:
CombiMatrix Molecular Diagnostics Launches Nationally Its Technical Only Program for Reference Laboratories



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that, after a successful beta test, its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has launched its innovative, Bacterial Artificial Chromosome (BAC) array Comparative Genomic Hybridization (CGH) Technical Only Program (TOP) for reference laboratories and other clients. Two laboratories have established partnerships with CMDX under TOP.

Clinical diagnostic tests are typically comprised of two components, the technical, wet-lab component and the professional medical-interpretation component. From a reimbursement perspective, these two components are considered independent of each other and billed separately. Most laboratories only offer their tests with these components combined, known in the industry as a "global service." CMDX offers its global service to all of its prescribing physicians and patients and now offers TOP for reference laboratory partners.

Though they recognize the value of array-based diagnostics, few laboratories have the technical expertise and capabilities to offer such tests by themselves. However, they do have licensed medical professionals capable of interpreting the tests. Seeking to expand its sales and marketing reach, as it expands its menu of BAC array CGH tests, CMD has launched TOP. TOP partners will market CMDX array services to their clients and contract for services with CMDX. After partners receive orders and samples, they will be sent to CMDX's CLIA Laboratory, where all testing will be completed (the technical portion). The partner is provided the data electronically, whereupon interpretation is completed by the partner's medical director (the professional portion), and the professional medical interpretation fee is billed.

This program enables incorporation of array CGH testing into any laboratory's menu, creates a revenue stream for the lab, and provides greater customer reach for CMDX. CMDX has beta-tested this program initially and has now launched it nationally. CMDX encourages domestic and international laboratories interested in this program to contact CMDX (www.cmdiagnostics.com).

"Our TOP client option for array CGH testing is revolutionary in many regards. First and foremost, it dismantles the 'black-box' image of so many new emerging genomics tests and openly presents the data in a readily interpretable, concise, and transparent manner," explains Dr. Mansoor Mohammed, President and CEO of CombiMatrix Molecular Diagnostics. "While technical only services exist as a component of the laboratory industry for routine genetic testing, we are the only laboratory to begin offering this service for array-based tests."

"CMDX's TOP has allowed us to transform our diagnostic laboratory by incorporating sought-after array-CGH testing services into our test menu, without having to invest in increasing staff or buying equipment," explains Dr. Greg Mengden, Laboratory Director of Southwest Genetics Laboratory, San Antonio's largest private genetics reference laboratory. "We needed to incorporate array-CGH testing into our diagnostic menu to provide the best options to our clients. After considering a number of options, we chose to ally with CMDX and have been sending patient samples to Irvine for 6 months."

"We recently opened our molecular diagnostics reference laboratory at the University of Michigan, and recognized that we could efficiently incorporate BAC array CGH testing into our repertoire with TOP," explains Dr. Ram Iyer, Director, Molecular Genetics. "We feel this alliance will be very successful for both organizations."

[wiwifant]

CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Prognostic for the Management of Chronic Lymphocytic Leukemia



NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation of the first of its HemeScan(TM) suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests. The test is designed to detect prognostic markers in chronic lymphocytic leukemia (CLL) and is now available to the clinical community through both routine clinical sample processing as well as through CMDX's innovative Technical Only Program for reference laboratories. This array is the industry's first clinically validated cancer diagnostic based on BAC array CGH.

CLL is the most common adult leukemia in the western hemisphere. There are approximately 10,000 new cases diagnosed in the U.S. each year with approximately 150,000 patients living with the disease at any given time. Patients diagnosed with CLL exhibit highly variable clinical courses, with some progressing rapidly to aggressive disease and death, while others exhibit an indolent state throughout a major portion of their normal life expectancy. Hence, the concept of prognosis at diagnosis is particularly relevant in CLL. Recent studies have shown a direct correlation between specific genomic imbalances and disease course. For example, CLL patients who have a deletion of 17p involving the p53 tumor suppressor gene typically progress to aggressive disease and death in a matter of months. Other patients exhibiting the same symptoms, but with duplication of chromosome 12 or deletion of 13q14, can live for a dozen years before their disease progresses. Similarly, other genomic aberrations have an impact on clinical course, and knowledge of these enables a personalized course of treatment.

HemeScan is designed to identify all of the known prognostic genomic imbalances relevant to the clinical course of CLL. By replacing the time-consuming and often subjective manual enumeration of several Fluorescent In Situ Hybridization (FISH) probe signals, HemeScan offers an innovative approach to prognosis at diagnosis, and hence better disease management.

"Our HemeScan for CLL Prognostic markers is the first CMDX oncology product from our HemeScan suite and is expected to be followed by additional hematology/oncology tests shortly," said Dr. Shelly Gunn, Medical Director of CombiMatrix Molecular Diagnostics. "Our entry into the cancer-prognostic arena comes on the heels of intense research and further highlights the powerful strategic value of our partnership with the world-renowned Centre for Applied Genomics in Toronto."

According to Gabriel Khodr, Medical Director of Southwest Genetics, San Antonio's largest private genetics laboratory, "By virtue of its recent product introductions, CMDX is establishing itself as a premier molecular-diagnostic company. It is exciting to see microarray products mature to a point where they can have significant impact on ill patients. We have been offering CMDX's CA650 test for several months and are now going to offer HemeScan to our clients. We feel that array-based tests are transforming genomic evaluation and management of patients and that CMDX's ability to rapidly introduce new products is exciting and ground breaking."

According to Dr. Joel Chan, Medical Director of Pathology Inc., a leading provider of pathology testing services in Southern California, "We have collaborated with CMDX for the clinical validation of its HemeScan and we are very pleased with the performance and robustness of the test. We look forward to incorporating this transformative test into our clinical test menu through CMDX's innovative Technical Only Program (TOP)."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 63 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Source: Acacia Research Corporation